 
Participating Organizations: Alliance/Alliance for Clinical Trials in Oncology (lead); ECOG -ACRIN/ECOG -ACRIN 
Medical Research Foundation, Inc; NRG/NRG Oncology Foundation, Inc; SWOG/SWOG  
 
Version Date 09/26/18 Update #10  
 1 ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY  
 
CALGB [ZIP_CODE]  
The Men‚Äôs Eating and Living (MEAL) Study: A Randomized Trial of Diet to 
Alter Disease Progression in Prostate Cancer Patients on Active Surveillance  
 
Study Chair  
J. Kellogg Parsons, M.D.,  MHS 
Moores Cancer Center  
University of [LOCATION_004], San Diego  
 
 
 
 
Study Co -Chair and Prevention Subcommittee Chair  
 
 
 
 
Prevention Subcommittee Co -Chair  Quality of Life Subcommittee Co -Chair  
  
  
 
 
Correlative Science Co -Chair  Pathology Co-Chair  
  
 
  
 
 
GU Surgery Co -Chair  CCHO Commi ttee Chair  
  
  
 
Primary Statistician  Staff Statistician  
 
 
 
  
 
Data Manager  Protocol Coordinator  
  
 
 
  
 

CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
2 Alliance 
Central Protocol Operations Program  
 
 
 
 
Allian
ce Statistics and Data Center  
Mayo Clinic  
 
 
Alliance Patient Registration  
 Alliance Biorepository at  
Ohio State University  
The Ohio State University  
Department of Pathology  
 
 
 
 
CALGB [ZIP_CODE] Nurse Liaison  
 
 
 
CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_862577]:  For patient 
enrollments:  Submit study data directly to the 
Lead Cooperative Group  
CTSU Regulatory Office  
 
 
 
 Please refer to the 
patient enrollment 
section for instructions on using the OPEN system.  Forms must  be submitted electronically 
using the ‚ÄúSubmit to CALGB‚Äù button 
located at the bottom of the l ast page 
of each form (see Section 6.1).  
 
Do not submit study data or forms to CTSU Data Operations. Do not copy the 
CTSU on data submissions.   
The study protocol and all related forms and documents  must be downloaded from the 
protocol -specific Web page of the CTSU Member Web site located at https://www.ctsu.org.  Sites 
must use the current form version and adhere to the instructions and submission schedule outlined in the protocol.  
CTSU sites should follow procedures outlined in the protocol for Site registration, Patient 
Enrollment, Adverse Event Reporting, Data Submission (including ancillary studies), and Drug 
Procurement.  
For patient eligibility or treatment -related questions  contact [CONTACT_64362] . 
For questions unrelated to patient eligibility, treatment, or data submission  contact [CONTACT_355339] e- mail:  CTSU General Information Line ‚Äì , or 
 All calls and correspondence will be triaged to the appropriate CTSU 
representative.  
For detailed information on the regulatory and monitoring p rocedures for CTSU sites  please 
review the CTSU Regulatory and Monitoring Procedures policy located on the CTSU members‚Äô website https://www.ctsu.org.  
The CTSU Web site is located at  https://www.ctsu.org. 
Endorsing cooperative group : 
SWOG  SWOG Coordinating Center  
  
  
  

CALGB [ZIP_CODE] 
9HUVLRQ'DWH  8SGDWH 
3 The Men‚Äôs Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease 
Progression in Prostate Cancer Patients on Active Surveillance 
Preregistration Eligibility Criteria Required Initial  
Laboratory Values Biopsy-proven adenocarcinoma of  the prostate, clinical stage ¬î7D  
diagnosed within 24 months prior to  pre-registration (see Sec. 4.1.1) 
Less than 25% of biopsy tissue cores posi tive for cancer. Serum PSA < 10 ng/mL 
d 50% of any one biopsy tissu e core positive for cancer. 
Patients who have prostate cancer with  distant metastases are not eligible. 
Patients who have had prior treatment for prostate cancer by [CONTACT_44850], irradiation, local ablative or   
androgen deprivation therapy are not eligible. 
Patients with a history of non-cutaneous malignancy in the previous [ADDRESS_1202430] 3 years. Patients may be currently taki ng vitamin supplements includin g lycopene and beta-carotene. 
Patients receiving treatment with 5-alpha reductase inhibitors with in 90 days prior to preregistration are not 
eligible (see Section 4.1.7). 
Patients who are currently taki ng coumadin are not eligible. 
Participants will be men aged 50 to 80 years. 
For men d \HDUVELRSV\*OHDVRQVFRUHPXVWEH¬îIRUPHQ!\HDUV ELRSV\*OHDVRQVFRUHPXVWEH¬î
(3 + 4) = 7. 
Registration/Randomization Eligibility Criteria 
Successful completion of thr ee 24-hour dietary recalls du ring the run in period 
Patients consuming t 6 servings per day of fruits and vegetables (not including juices) are not eligible. 
Schema
P 
R 
E 
R 
E 
G 
I 
S 
T 
E 
R   
R 
E 
G 
I 
S 
T 
E 
R   
    Arm A: MEAL Program Intervention 
with dietary education and telephone counseling sessions over 24 months  
Run In:  Diet 
Recall   
  
   
   
Arm B: Prostate Cancer Foundation 
booklet   
  
Stratification:   
xAge: Men d \HDUV0HQ!\HDUV  
xRace: Black or African American vs. Other 
xBaseline Prostate Biopsy: 0-12 PRQWKVSULRUWRUHJ LVWUDWLRQYV! -24 months prior to 
registration 
MEAL Program Intervention: The counseling protocol will be divided into four phases, with the 
first three phases completed in 7 months. The fourth phase will continue for 17 months.  
‚Ä¢ The first phase , comprised of six counseling calls, will focus on education and the rapid 
development of self-efficacy.  
‚Ä¢ The second phase , comprised of four calls over a 2-month period, will focus on practical 
and consistent implementati on of the dietary pattern. 
‚Ä¢ The third phase , comprised of four calls over a 4-month period, will help participants 
habituate to the dietary pattern by [CONTACT_862578]. 
‚Ä¢ The fourth phase , comprised of 8 calls over a 17-month period, will be a maintenance 
phase. 
Quality of Life Measures: Seven quality of life measures will be used: Personal Habits 
Questionnaire, Functional Assessment of Cancer Therap y Scale-Prostate (FACT- 3 0HPRULDO
Anxiety Scale for Prostate Cancer (Max- 3&,QWHUQDWLRQDO3URVWDWH6\PSWRP6FRUH,366([SDQGHG
Prostate Cancer Index Composite 26 (EPIC- 1XWULWLRQ6HOI ‚ÄìEfficacy and MEAL Study Counseling 
Evaluation Form.  

CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
4  
 
TABLE OF CONTENTS  
  SECTION  PAGE  
1.0  INTRODUCTION ................................................................................... 5 
2.0 OBJECTIVES ....................................................................................... 13 
3.0 ON STUDY GUIDELINES ..................................................................... 13 
4.0 ELIGIBILITY CRITERIA ........................................................................ 13 
5.0 REGISTRATION ................................................................................... 14 
6.0 DATA SUBMISSION AND SAMPLE SUBMISSION ................................. 17 
7.0 REQUIRED DATA ................................................................................ 23 
8.0 INTERVENTION ................................................................................... 24 
9.0 OUTCOMES ASSESSMENT/QUALITY OF LIFE MEASURES ................. 29 
10.0 CORRELATIVE STUDIES ..................................................................... 33 
11.0 STATISTICAL CONSIDERATIONS ......................................................... 38 
12.0 REFERENCES ..................................................................................... 41 
13.0 MODEL CONSENT FORM .................................................................... 48 
14.0 MODEL CONSENT FORM: Addendum for patients who consented to 
participate in the embedded companion study to [ZIP_CODE] prior to the approval of 
Update 8 ....................................................................................................... 58 
 
  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
5 1.0  INTRODUCTION  
1.1 Prostate Cancer: The Concept of Overtreatmen t 
Prostate cancer is the most commonly diagnosed non -cutaneous cancer among US men. 
Approximately 192,000 new cases were identified in 2009 (1). Although prostate cancer is 
the second leading cause of cancer death among US men, the probability of dying fro m 
prostate cancer is relatively low. The lifetime risk of prostate cancer diagnosis is 16%, but the lifetime risk of death from prostate cancer is only 3% (1). This discrepancy between prostate cancer incidence and mortality, due in large part to detection of pre -symptomatic 
tumors by [CONTACT_862579] -specific antigen (PSA) assay, is distinct among cancers. As a 
result of widespread PSA testing, 50% of newly diagnosed prostate cancer patients now 
present with localized, lower -risk disease (2).  
Most patients with lower -risk prostate cancer are treated with surgery or radiation (3). 
Although the probability of cure with these modalities is high, both are associated with 
urinary, bowel, and sexual morbidities that significantly diminish quality of life (4, 5). More over, despi[INVESTIGATOR_862547]- free, whether 
the treatments actually reduce prostate cancer -specific or overall mortality in lower -risk 
patients is not known. Many men with localized, higher -risk prostate cancer have 
aggressive disease that warrants aggressive intervention (6); many others, with lower -risk, 
generally indolent prostate cancer, even younger men likely to live 15 years or more from 
diagnosis, derive few, if any, survival benefits from treatment (7 -10). 
Population studies suggest that a substantial proportion of men diagnosed with lower -
risk prostate cancer in the US are over -treated (2 -4). In a recent study of the US SEER 
registry, Miller and colleagues concluded that approximately 50% of men with lower -risk 
prostate cancer received unnecessarily aggressive treatment, surgery or radiation (4). The 
staggering scope of this public health problem that is, unnecessarily aggressive treatment of lower risk prostate cancer, treatment that diminishes quality of lif e for tens of 
thousands of US men each year, challenges us to develop innovative therapeutic and 
diagnostic models to refine treatment paradigms within this patient population.  
1.2 Active Surveillance (AS) for Lower -Risk Prostate Cancer  
The concept that su bstantial proportions of men diagnosed with lower -risk prostate 
cancer are over -treated has fostered growing interest in a management approach known 
as active surveillance (AS). AS entails vigilant monitoring of men with localized, lower -risk 
prostate cancer by [CONTACT_862580], frequent digital rectal examinations, and 
intermittent prostate biopsies. Intervention with surgery, radiation, or other therapi[INVESTIGATOR_862548] (9,11 -16). 
Active surveillance protocols for identification of patients with lower -risk disease vary by 
[CONTACT_14189], but are generally similar. Clinical criteria for enrollment in a surveillance 
program typi[INVESTIGATOR_862549] < 10 ng/mL, tumor that is non -palpable, or palpable 
but small on digital rectal examination (clinical stage T1 or T2) and lower -risk tumor 
characteristics on prostate biopsy, namely, low -grade (Gleason sum ‚â§ 6) and low- volume 
(tumor evident only in a small number and percentage of biopsy cores) disease (9,11 -16). 
Similarly, while there remains no clinical consensus, disease progression while on surveillance is broadly defined as a rapi[INVESTIGATOR_862550] (manifested as decreased PSA doubling time or increased PSA velocity) or worrisome pathology on repeat biopsy  
(Gleason score ‚â• 7 or increased tumor volume) (9,11 -16). 
In carefully selected men with lower -risk prostate cancer, AS is a viable and safe 
treatment option. Warlick and colleagues, confirming earlier results (9), observed that patients followed on AS for  up to [ADDRESS_1202431] as likely to be cured of their disease as men who 
underwent surgery immediately after diagnosis (14).  
Approximately 30% of patients on AS will progress based  on current PSA or pathological 
criteria and thus receive intervention with surgery or radiation, typi[INVESTIGATOR_16195] 2 years of 
beginning surveillance (11). The Hopkins data indicate that 31% of patients progress 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
6 within 26 months (13, 15). In the Toronto coh ort, 34% progressed after 64 months; 
however, the definition of progression for most of the follow -up period was based on a PSA 
DT of 2 years or pathology progression to Gleason grade 8. Klotz estimated that 20 
percent of patients would progress on the basis of a PSA DT of 3 years, while 5 to 10% would progress on the basis of tumor grade progression. Moreover, up to 12% of men who do not meet objective criteria for progression will opt for intervention (11). Thus, in total, over 40% of men on AS will progr ess or proceed to treatment. Reducing the proportion of 
men who progress or choose treatment while on AS for prostate cancer represents a novel opportunity to minimize treatment- associated morbidity, improve patient quality of life, 
and contain health care  costs.  
1.[ADDRESS_1202432] in the role of diet in the etiology and natural history of prostate cancer (17, 18). Accumulating evidence suggests that diet may alter prostate cancer initiation and progression. Macronutrients and micronutrients associated with decreased prostate cancer risk include retinoids, 
carotenoids (particularly lycopene), cruciferous vegetables, dietary fat, soy products, 
folate, retinol, vitamin D, and omega fatty acids (17- 23). A range of phytochemicals in 
fruits and vegetables could have effects on a metabolically active organ like the prostate, 
and a number of plausible mechanisms have been proposed (24 -39). 
Experimental studies based on cell line and animal models suggest that vegetable intake 
may lessen the risk or retard the progress of prostate cancer. Rats fed tomato powder have decreased prostate- cancer specific mortality compared to controls (24) and, in vitro, 
lycopene inhibits DNA synthesis in prostate epi[INVESTIGATOR_1663] (25). Cell line and animal data support the anti -carcinogenic properties of isothiocyanates, which are components of 
cruciferous vegetables such as broccoli and cabbage. Isothiocyanates induce expression of cytoprotective phase 2 enzymes in multiple prostate tumor cell lines (26, 31) promote apoptosis of prostate cancer P C-3 cells in vitro, and inhibit growth of PC -3 xenografts in 
nude mice (28). In a prostatectomy model, men fed a tomato intensive diet had distinct 
biological changes potentially associated with suppression of prostate tumors (30).  
Indirect evidence from epi[INVESTIGATOR_623], ecological, case -control and cohort studies in 
humans suggests that altering nutritional intake may provide beneficial effects against 
prostate cancer (18). This evidence suggests a diet that emphasizes vegetable intake and de-emphasizes meat and fat intake may decrease the risk of prostate cancer initiation 
and progression. The most direct evidence for this supposition has been provided by [CONTACT_862581]. Red meat and fat intakes tend to be associated with in creased risk (particularly of aggressive cancer); cruciferous vegetables 
and tomatoes and tomato products tend to be most closely associated with decreased risk 
(20-23, 33).  
Recent observational data also indicate that weight loss may alter the natural hi story of 
prostate cancer: among men in the Cancer Prevention Study II Nutrition Cohort, weight 
loss >11 lbs over 10 years was associated with a 40% reduction for high -grade cancer risk 
(34). Follow up of the Prostate Cancer Prevention Trial cohort indicated that a BMI > 30 kg/m
2 was associated with an 18% decreased risk of low -grade prostate cancer and a 
29% increased risk of high -grade prostate cancer (35). Low serum cholesterol was 
associated in this same study with decreased risk of high grade prostate cancer (36).  
To date, human experimental evidence supporting epi[INVESTIGATOR_862551]- clinical findings, 
though intriguing, is limited. Isothiocyanates derived from cruciferous vegetables enter 
the human prostate following oral consumption and may be associate d with anti -
carcinogenic, phase 2 enzyme activity in prostate tissue (29, 31). In a small intervention 
study, patients with recurrent prostate cancer experienced decreased PSA doubling times six months after beginning treatment with diet modification and stress reduction (37). In another small clinical trial of active surveillance patients, randomization to a plant -based 
diet with micronutrient supplements and intensive lifestyle changes resulted in decreased 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
7 serum PSA concentrations, inhibition of prostate  cancer cell growth, and progression to 
active treatment; (38) another non -randomized pi[INVESTIGATOR_862552] a similar intervention 
(plant based whole foods coupled with exercise and stress management) resulted in 
significant changes in prostate gene expression (39).  
These studies provide preliminary clinical evidence that diet change may slow prostate 
cancer progression. Still, they were small studies with only short -term (~ 1 year) follow-
up. Moreover, as it is impossible to isolate the effects of diet from those of exercise, stress management, and group support, these changes in PSA and cancer cell growth cannot with certainty be attributed solely to dietary change. On the other hand, the most likely factor driving these changes is diet. In addition, whether intensive lifestyle modifications such as exercise, yoga, and stress management would be practicable, sustainable behaviors in large groups of patients remain to be seen. An adequately powered trial, focusing on diet as a primary form of intervention, i s needed.  
We previously designed and implemented a telephone- based dietary intervention for 
prostate cancer patients based on well -established principles of social cognitive theory. 
This relatively straightforward intervention, the first to use diet change as a primary 
treatment for low risk prostate cancer, produced robust, beneficial diet changes (i.e. 
significantly increased vegetable intakes) and led to increased plasma levels of potentially 
anti-carcinogenic carotenoids in prostate cancer patients (40 -42). We believe that the next 
step is to determine, in a suitable study sample, whether these diet changes, marked by [CONTACT_862582], will exert a clinically relevant and sustainable effect 
on prostate cancer progression.  
1.4 Dietary In tervention in an Active Surveillance (AS) Population  
Men on AS represent a compelling population for studying diet change and prostate 
cancer for at least [ADDRESS_1202433], approximately 100,000 men are diagnosed with lower -
risk prostate cancer every year in the US. Some 42% of men on AS progress to treatment 
(30% because of disease progression, 12% because of anxiety); reducing this proportion 
represents a realistic and valuable therapeutic and public health goal (8, 9, 11, 13). Second, clinically localize d, lower -risk cancer may potentially be more affected by [CONTACT_862583], aggressive disease. If diet is related to the risk of prostate cancer, it may well exert an impact on the earliest phases of prostate cancer; its impact may best be  tested in an AS population. Third, AS patients are not receiving active 
therapy (i.e. radiation, surgery, or androgen) that would otherwise obscure or modify any beneficial effects of dietary change. Finally, AS patients would likely be receptive to nutritional interventions with proven benefits for cardiovascular and overall health (8, 11, 
43). 
Indeed, because prostate cancer diagnosis is a source of considerable anxiety and 
diminished quality of life for many patients diagnosed with lower -risk disease (44-46), 
dietary change might not only exert therapeutic biological effects on the tumor, but might also encourage men with lower -risk prostate cancer and no signs of progression to remain 
within an AS program. As previously noted, up to 12% of patients wi th no objective PSA 
or pathologic indications of progression nonetheless opt for treatment that may not improve their prognosis (11). Treatment preferences in this situation are generally believed to arise, to a large extent, from patient anxiety and discomfort over not receiving curative therapy. This attitude is likely fostered by [CONTACT_862584] -oriented approach that 
characterizes our current health care system (8). However, prostate cancer -related anxiety 
and its effects on treatment choice have not as yet been prospectively studied in an AS 
population. 
Diet change presents an ideal opportunity for AS patients to alter the perception of their 
disease by [CONTACT_862585]. This approach may dissuade 
otherwise lower -risk men from purs uing unnecessarily aggressive, morbidity- generating 
treatments. Such an approach would promulgate a novel therapeutic paradigm for lower -
risk prostate cancer: medical management, without radical intervention, in a chronic 
disease state.  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202434] documented fear of recurrence to be highly prevalent in a number of different cancer patient populations (47- 50). Cancer surviv ors may experience lingering psychological 
sequelae, including fear of diagnostic tests and fear of recurrence for long periods of time 
after diagnosis and treatment (53).  
Prostate cancer patients are not immune to worry over their disease (5, 44 -46, 52, 5 3). 
However, treatment may also diminish fear of recurrence. Among prostate cancer patients 
undergoing definitive treatment, fear of recurrence peaked prior to treatment, then decreased within 6 months after treatment (52). A possible explanation for this finding is that patients were reassured about their prognosis after having undergone treatment. Providing prostate cancer patients the opportunity to exert control over a change in their 
dietary intake, a diet- based intervention may perhaps help patients o vercome fear of 
recurrence, particularly if the intervention stabilizes PSA.  
Part of the impact of a diet change program may involve social cognitive theory, which 
governs most current attempts to change behavior. A key element of social cognitive theory is self -efficacy. According to social cognitive theory, the interaction of the  
individual with the environment is influenced by [CONTACT_862586], expectation of behavioral outcomes, and evaluation and modification of behavior toward specific goals (54). Components of social cognitive theory include sel f-efficacy 
(confidence in ability to perform a particular behavior to accomplish a specific goal), outcome expectancies (belief that a particular behavior will result in a particular consequence), and self -regulation (adopting personal standards for behavi or, appraising 
behavior against such standards, and creating incentives that motivate and guide behavior). Participating in diet change, as in this study, may increase patient feelings of self-efficacy, defined as their ‚Äújudgments of their capabilities to organize and execute 
courses of action required to attain designated types of performance (55 -57).‚Äù According 
to Bandura (56), mastery experiences are the most reliable source of efficacy information. Applied to this study, feelings of greater self -efficacy will increase patients‚Äô ability to 
control their diet and consequently their health. Identifying and reinforcing patients‚Äô present success is a factor that Bandura (54, 56), and Strecher and colleagues (58) 
suggest clinicians use to improve self -efficacy . Building a sense of self -efficacy is part of 
the MEAL program. Self- efficacy has been incorporated into various interventions: self -
management interventions and educational programs in patients with chronic disease 
(61) and prostate cancer (57). Breast a nd colon cancer patients randomized to either an 
educational or nutritional intervention arm had significantly fewer depressive symptoms and better physical functioning than patients in the control group, primarily accounted for by [CONTACT_6270] -efficacy (60). Canc er patients with greater self -efficacy have been found to be 
better adjusted and have a better overall quality of life (55, 57-59).  
We expect that participating in the MEAL intervention will improve the quality of life for low risk prostate cancer patient s. The literature is largely supportive, indicating that this 
intervention‚Äôs focus on self -efficacy will add measurably to quality of life (56 -63). One of 
the implicit messages that participants take from being in this study will be that low risk prostate cancer is a condition to monitor, but neither a death sentence nor a condition 
that requires radical, immediate, life -changing intervention. We will not be able to 
compare trial participants to non -participants. We will, however, be able to compare those 
randomized to the diet change to those randomized to the comparison group.  
Low risk prostate cancer is a substantial public health issue that affects tens of thousands of men each year in the US. Epi[INVESTIGATOR_50123], pre -clinical, and preliminary 
clinical studies  suggest that diet is related to prostate cancer risk, so that changing to a 
high-vegetable diet may decrease prostate cancer progression in lower risk patients. 
Clearly, mature clinical data on use of diet to treat prostate cancer are lacking. We have developed a novel, practical, telephone- based intervention that has been shown to 
increase vegetable intake and serum carotenoid levels in men with prostate cancer. We 
propose to document the impact of this dietary intervention in an extended clinical trial 
using prostate cancer patients under AS; for such patients, the likelihood of treatment 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
9 efficacy, even after delay, is relatively high. Patient anxiety is a prominent yet 
understudied complaint among AS patients; diet change may decrease prostate -cancer 
related anxiety among these patients. Further study of diagnosis -related anxiety will yield 
potentially important information for improving the psychological care of prostate cancer 
patients. 
1.6 Pi[INVESTIGATOR_862553]: The Women‚Äôs Healthy Eating and Living 
(WHEL) Study for Breast Cancer  
A CALGB pi[INVESTIGATOR_862554]‚Äôs Healthy Eating and Living study (WHEL), a multi- center 
trial of diet change for breast c ancer (40 -42,64). Utilizing well- established behavior 
change techniques, this intervention achieved substantial changes in vegetable, fiber and 
fruit consumption, along with a substantial change in fat consumption (64).  
The dietary intervention we developed employs telephone -based communication. The 
conceptual framework of the intervention is derived from Social Cognitive Theory (54), 
which emphasizes strengthening of individual self -regulatory skills, including goal-
setting, self -monitoring and evaluative judgments. We utilize lay coaches to help 
participants frame options for decisions. The coaches focus on self -efficacy, or participant 
belief that they can actually succeed in behavior change (64, 65). The lay coaches also provide a supportive environment for regular discussion of triumphs and failures as 
participants seek to change.  The lay coaches are well versed in basic nutrition, and they are supervised by [CONTACT_862587]; nonetheless, they function 
less as authority figures than as facilitators or guides, and as supporters, helpi[INVESTIGATOR_862555] (66).  
The intervention efforts are timed so that they provide the greatest support and guidance 
when the challenges of change, henc e the threats of failure, are greatest: at the beginning 
(65). We have demonstrated that major changes can be implemented during the first 
month of the intervention (40 -42, 65). The subsequent challenge is to integrate change 
into the participant lifestyle , then to reinforce and maintain the change. The counselors 
during this time watch for signs that participant self -efficacy is waning; declining self -
efficacy may be an indicator that failure is increasingly likely (65). We have shown that 
this approach re sults in substantial dietary change that can be maintained for several 
years (67).  
This telephone -based approach has been shown to result in change that can be seen in 
accepted biomarkers of nutritional practice (40- 42). Carotenoids, which are fat -soluble 
pi[INVESTIGATOR_862556], accumulate in blood. The most common of these, alpha carotene, beta -carotene, lutein, lycopene and crytoxanthin, 
reflecting the intake of a wide range of plants, were used as general biomarkers of  plant 
intake (65). The WHEL study intervention, on which our pi[INVESTIGATOR_862557], caused the diets and blood carotenoids of 1500 experimental subjects and 1500 control subjects to diverge substantially within a year of beginning the intervention; after that, we observed, 
over a period of 3 to 4 years, a slight decline in the difference between the dietary practices of experimental and control subjects (66). Nonetheless, experimental subjects in the WHEL study spent the bulk of their study participation time consuming a diet that was radically different than both their pre- enrollment diet and that of comparison 
subjects.  
A nuance of diet change trials is that subjects are not blinded to their assignment; thus, there is always a possibility that subject beh avior will be changed by [CONTACT_862588]. In particular, experimental subjects may be inclined to exaggerate their compliance with diet goals. Subjects cannot, however, readily exaggerate their blood 
carotenoid levels except by [CONTACT_862589]. These are integrated over an extended 
period, and experimental subjects are unlikely to change these other than by [CONTACT_862590].  
While it is certainly true that any methodology involving prospective dietary change poses 
challenges, the W HEL data, and the to -be discussed MEAL data, indicate that we can 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202435] cancer events among women without hot flashes who had higher vegetable, fruit and fiber and lower fat intakes (70).  These data tentatively 
support the notion that diet change may alter the natural history of breast cancer in 
select groups of patients.  
1.7 The Men‚Äôs Eating and Living (MEAL) Pi[INVESTIGATOR_862558], we designed and implemented a pi[INVESTIGATOR_862559]: the Men‚Äôs Eating and Living (MEAL) Study (40 -42). This randomized, controlled clinical pi[INVESTIGATOR_369737] [ADDRESS_1202436] the patient, to participate in the diet counseling. The study demonstrated that diet change with telephone -based counseling results in increased vegetable intake and increased plasma 
carotenoid concentrations among men with prostate cancer.  
Dietary changes: vegetables  
Consistent with counseling targets, vegetable intakes in the intervention arm increased significantly at six months, while those in the control arm remained static  (Table 1). Diet 
was measured by a series of three 24 -hour recalls collected interactively via telephone 
interview. In the intervention arm, mean daily intakes of total vegetables, crucifers, tomato products and other vegetables increased by 76%, 143%, 292%, and 55%, respectively. The intervention emphasized vegetable, rather than fruit intake, and white potatoes and lettuce did not count. As a result, fruit, lettuce, and potato intake declined for experimental subjects (40 -42). In the control arm, there we re no significant changes in 
mean intakes of total vegetables, crucifers, tomato products, lettuce and potatoes, or 
other vegetables.  
Table 1. Vegetable intake* at baseline and 6 months as assessed by 24 hour  
dietary recall in the Men‚Äôs Eating and Living ( MEAL) Study  
 Intervention  
n=45  Control  
n=23  
 Baseline  6 
Months  Change  Baseline  6 
Months  Change  
Total 
vegetables  4.1 7.2 76%‚Ä†‚Ä° 3.7 4.2 12% 
Cruciferous vegetables  0.7 1.7 143%‚Ä†‚Ä° 0.4 0.6 44% 
Tomatoes 0.6 2.3 292%‚Ä†‚Ä° 0.7 0.8 5% 
Lettuce and 
potatoes  1.0 0.4 -58%‚Ä†‚Ä° 0.6 0.6 -3% 
Other vegetables  1.8 2.8 55%‚Ä† 1.9 2.2 12% 
            *All intakes measured in servings per day  
            ‚Ä†Significant difference (p<0.05) between groups  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
11             ‚Ä°Significant difference (p<0.05) within groups  
Dietary changes: non- vegetables  
Intakes of whole grains and beans in the intervention group increased, while fat intake 
decreased; mean daily intakes of whole grains and beans increased by 28% and 95%, 
respectively, while fat intake decreased by 12% (p<0.05). In the contr ol arm, whole grain 
and fiber intakes decreased by 33% and 21%, respectively (p<0.05), and there were no 
significant changes in fruit, beans, fiber, or fat intakes (data not shown) (40 -42). 
Plasma carotenoid concentrations  
Consistent with increased vegetable consumption, carotenoid concentrations increased in 
the intervention but not in the control group (Table 2). At baseline, plasma total carotenoid concentrations of intervention and control participants were virtually the same. At six months, however, th ose of intervention and control participants, 
respectively, rose by 26% and 3% (p=0.02). In the intervention group, Œ±-carotene, Œ≤-
carotene, lutein, and lycopene concentrations increased significantly, while those in the control group remained static (p<0.05). Cryptoxanthin levels changed in neither group. That the changes observed were qualitatively larger than those observed in such prevention interventions as the Polyp Prevention Trial (69) suggests that this test of dietary intervention might be much more sensitive and powerful than either the Polyp 
Prevention Trial or the Women‚Äôs Health Initiative (70).  
Although the MEAL study w as not strictly intended for AS patients, the patients on AS 
(53% of the study sample) experienced dietary change and plasma carotenoid results 
identical to those for the entire group (42).These data support the feasibility of implementing a larger clinical trial of a telephone -based diet intervention in men with 
prostate cancer treated with AS.  
Our data, which include blood -based biomarkers, indicate that experimental subjects 
changed their diets, but that comparison subjects did not. Other data, including  the 
Polyp Prevention Trial (71) and the Women‚Äôs Healthy Eating and Living study (66), confirm that comparison subjects in diet intervention trials in general do not change their 
diets to nearly the extent that experimental subjects do.  
Table 2. Plasma carotenoid concentrations at baseline and 6 months in the Men‚Äôs Eating and Living (MEAL) Study  
Carotenoid 
(mmol/L) Intervention  
n=45  Control  
n=23  
Baseline  6 Months  Change  Baseline  6 Months  Change  
Œ±-Carotene  0.17 0.23 33%‚Ä° 0.16 0.17 5% 
Œ≤-Carotene  0.61 0.83 36%‚Ä†‚Ä° 0.63 0.66 5% 
Lutein  0.44 0.53 19%‚Ä†‚Ä° 0.43 0.43 0 
Lycopene 0.79 1.03 30%‚Ä†‚Ä° 0.86 0.87 2% 
Cryptoxanthin  0.19 0.17 -11% 0.17 0.18 11% 
Total Carotenoids  2.21 2.79 26%‚Ä†‚Ä° 2.24 2.32 3% 
         ‚Ä†Significant difference (p<0.05) between groups  
         ‚Ä°Significant difference (p<0.05) within groups  
MEAL: Program satisfaction  
The response to the intervention was almost universally positive. In a very preliminary attempt to document the extent to which the participants experienced this program positively, we administered a limited questionnaire to 33 of the participants. We asked 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
12 them to describe their satisfaction on a 5 -point scale, with 1 indicating strong 
dissatisfaction and 5 strong satisfaction. The responses were extremely positive; 31 of 33  
rated their counselor a 5 for being prompt and convenient with sessions; 30 of 33 rated 
the counselor a 5 for listening; 32 of 33 rated the counselor a 5 for being easy to talk to; 29 of 33 rated the counselor a 5 for knowledge; [ADDRESS_1202437] the counselo r a 5 for being 
helpful; [ADDRESS_1202438] the counselor a 5 for motivating them; and [ADDRESS_1202439] this practical, diet -
based intervention for prostate cancer in a broader clinical setting. Patients on AS will be 
randomized either to an intervention of centralized, telephone- based dietary counseling 
and structured dietary  education or to a comparison control condition in which they 
receive the Prostate Cancer Foundation booklet entitled ‚ÄúNutrition, Exercise and Prostate Cancer.‚Äù Study endpoints will include disease progression, incidence of treatment, and health- related qu ality of life.  
1.[ADDRESS_1202440] to prostate cancer, they will be excluded from this study. Efforts will be made to enroll individuals of all races and ethnic backgrounds, with the added goal of recruiting relatively high numbers of individuals of Hispanic origin and of African -American origin . The increased risk of prostate cancer and especially of lethal 
prostate cancer among African Americans makes it imperative that we secure adequate 
representation of African Americans in this study.  
CALGB has a long history of effort to ensure adequate r epresentation of minorities in all 
clinical trials, including prevention trials. The recent experience of the Selenium and 
Vitamin E Cancer Prevention Trial (SELECT) (80) is instructive: 29% of the CALGB participants were African Americans. In our MEAL pil ot study, 12% of participants were 
non-white. Our goal with the full MEAL trial is for 29% of participants to be members of 
racial minorities, especially African Americans.  
Racial Categories  DOMESTIC PLANNED ENROLLMENT REPORT  
Ethnic Categories  
Not Hispanic or Latino  Hispanic or Latino  
Total  
Female  Male Female  Male 
American Indian/Alaska Native  0 3 0 0 3 
Asian  0 9 0 0 9 
Native Hawaiian or Other Pacific 
Islander  0 1 0 0 1 
Black or African American  0 53 0 1 54 
White  0 381 0 16 397 
More Than One Race  0 0 0 00 0 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
13 Total  0 447 0 17 464 
2.0 OBJECTIVES   
2.1 Primary Objective  
To determine if a telephone- based dietary intervention compared to no intervention will 
decrease clinical progression in AS patients.  
2.2 Secondary Objectives  
2.2.1  To compare  the incidence of active treatment (surgery, irradiation, local ablation, or 
androgen deprivation) in AS patients receiving dietary intervention compared to no 
intervention.  
2.2.2  To compare prostate cancer -related anxiety in AS patients receiving dietary 
intervention compared to no intervention.  
2.2.3  To compare health -related quality of life in AS patients receiving dietary intervention 
compared to no intervention.  
[See Section 10.0 for correlative science objectives.]  
3.[ADDRESS_1202441] physicians in selecting patients for whom protocol 
therapy is safe and appropriate. Physicians should recognize that the following might increase 
the risk to the patient entering this protocol:  
‚Ä¢ Patients with medical conditions which, in the opi[INVESTIGATOR_021], would 
make this protocol unreasonably hazardous for the patient should not be enrolled. Such 
conditions may include uncontrolled chronic diseases (including uncontrolled diabetes 
mellitus, cardiac disease, u lcerative colitis, and Crohn‚Äôs disease); or psychiatric 
illness/social situations that would limit compliance with study requirements and/or 
prevent the patient from giving informed consent.  
‚Ä¢ Intolerance of cruciferous vegetables.  
‚Ä¢ Unwillingness to adopt  a vegetable- intense diet.  
4.0 ELIGIBILITY  CRITERIA  
4.1 Preregistration Eligibility  
4.1.1 Histologic Documentation: The initial biopsy showing diagnosis of prostate cancer 
should be used for the purposes of determining eligibility. However, if a subsequent  
biopsy performed before patient enrollment shows that the patient is ineligible, he 
may not be enrolled to the study.  Eligible patients must meet all of the following 
criteria:  
‚Ä¢ Biopsy -proven (consisting of ‚â•  10 tissue cores) adenocarcinoma of the prosta te 
diagnosed within 24 months prior to pre -registration .  
‚Ä¢ < 25% of biopsy tissue cores positive for cancer.  
‚Ä¢ ‚â§ 50% of any one biopsy tissue core positive for cancer.  
‚Ä¢ Clinical stage ‚â§  T2a. 
‚Ä¢ Patients who have prostate cancer with distant metastases are not eligible.  
NOTE: If a patient undergoes a transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH), and prostate cancer is diagnosed incidentally from the TURP specimen, eligibility for CALGB [ZIP_CODE] cannot be determined from  the 
TURP specimen. However, if the patient subsequently undergoes a minimum 10 -core 
prostate biopsy within 2 years of prostate cancer diagnosis from the TURP, and 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
14 prostate cancer is detected in the biopsy specimen and meets the requirements above, 
the patient is eligible for this study. If prostate cancer is not detected in the biopsy 
specimen, the patient is not eligible.  
4.1.2  Prior Treatment: Patients who have had prior treatment for prostate cancer by 
[CONTACT_44850], irradiation, local ablative (i.e. cryosurgery or high -intensity focused 
ultrasound) or androgen deprivation therapy are not eligible.  
4.1.[ADDRESS_1202442] had a history of non -cutaneous malignancy (other than non-
melanoma skin cancer) in the previous 5 years are not eligible.  
4.1.4  Language: Patients must be able to read and comprehend English language text and 
be able to understand spoken English over the phone.  
4.1.[ADDRESS_1202443] 3 years.  
4.1.6  Patients who are currently taking vitamin supplements including lycopene and beta-
carotene are eligible.  
4.1.7  Patients receiving treatment with 5 -alpha reductase inhibitors (e.g., finasteride, 
dutasteride) within 90 days prior to preregistration are not eligible. Treatment with 
these agents during the protocol intervention is not permitted. 
4.1.8  Patients who are currently taking coumadin are not eligible.  
4.1.9  Participants will be men aged 50 to 80 years.  
4.1.10  For men ‚â§  70 years, biopsy Gleason score ‚â§ 6; for men > 70 years, biopsy Gleason 
score ‚â§ (3 + 4) = 7.  
4.1.11  Required Initial Laboratory Values:  
‚Ä¢ Serum PSA < 10 ng/mL  
NOTE: Baseline PSA for determination of eligibility must be measured after 
discontinuation of any 5 -alpha reductase inhibitors.  
4.2 Registration Eligibility  
4.2.1  Successful completion of three 24 -hour dietary recalls during the run -in period.  
4.2.2  Patients consuming ‚â• 6 servings per day of fruits and vegetables (not including 
juices), as determined by [CONTACT_862591]- in dietary recalls are not eligible.  
5.0 REGISTRATION   
Informed Consent:  The patient must be aware of the neoplastic nature of his disease 
and willingly consent after being informed of the procedure to be followed, the experimental nature of the study, alternatives, potential benefits, side effects, risks and discomforts.  
Protected Health Informatio n: In order to contact [CONTACT_862592], it 
will be necessary to collect those participants‚Äô names, addresses, and telephone numbers. This information will be sent to the University of [LOCATION_004], San Diego Moores Cancer Center and will be  destroyed upon completion of the study.  
5.1 CTSU registration requirements  
This study is supported by [CONTACT_6818] (CTSU).  
Prior to the recruitment of a patient for this study, investigators must be registered members of a Cooperative Group. Each investigator must have an NCI investigator number and must maintain an ‚Äúactive‚Äù investigator registration status through the annual submission of a complete investigator registration packet (FDA Form 1572 with 
original signature, current CV, Supplemental Investigator Data Form with signature, and Financial Disclosure Form with original signature) to the Pharmaceutical Management 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
15 Branch , CTEP, DCTD, NCI. These forms are available on the CTSU Web site ( enter 
credentials at https://www.ctsu.org; then click on the Register tab ) or by [CONTACT_862593] 8:30 a.m. and 4:[ADDRESS_1202444] obtain IRB approval for 
this protocol and submit IRB approval and supporting documentation to the CTSU 
Regulatory Office before they can enroll patients. Study centers can check the status of their registration packets by [CONTACT_290546] (RSS) site 
registration status page of the CTSU member web site by [CONTACT_461484]://www.ctsu.org. 
Requirements for CALGB [ZIP_CODE] site registration:  
‚Ä¢ CTSU IRB Certification  
‚Ä¢ CTSU IRB/Regulatory Approval Transmittal Sheet  
5.[ADDRESS_1202445] occur prior to providing patients with access to the online patient 
data entry site, login information or training. Pre -registration to the optional companion  
studies will be performed at the time pre -registration occurs to the intervention study.   
All site staff  (Lead Group and CTSU Sites) will use OPEN to enroll patients to this study. 
OPEN can be accessed at https://open.ctsu.org or from the OPEN tab on the  CTSU 
members‚Äô side of the website at https://www.ctsu.org.  
Prior to accessing OPEN site staff should verify the following:  
‚Ä¢ All eligibility criteria have been met within the protocol stated timeframes. Site staff 
should use the OPEN Enrollment forms prov ided on the group or CTSU web site as a 
tool to verify eligibility.  
‚Ä¢ All patients have signed an appropriate consent form and HIPAA 
authorization  form (if applicable).   
Access requirements for OPEN:  
‚Ä¢ Site staff will need to be registered with CTEP and have a valid and active CTEP -IAM 
account. This is the same account (user id and password) used for the CTSU members' web site.  
‚Ä¢ To perform registrations, the site user must have been assigned the 'Registrar' role on the relevant Group or CTSU roster.  
‚Ä¢ To perform registrations on protocols for which you are a member of the Lead Group, 
you must have an equivalent 'Registrar' role on the Lead Group roster.  Role 
assignments are handled through the Groups in which you are a member  
‚Ä¢ To perform registrations to trials accessed via the CTSU mechanism (i.e., non -Lead 
Group registrations) you must have the role of Registrar on the CTSU roster. Site 
and/or Data Administrators can manage CTSU roster roles via the new Site Roles maintenance feature under RSS on the CTSU members' web site. This will allow them 
to assign staff the "Registrar" role.  
The OPEN  system will provide the site with a printable confirmation of pre -registration. 
Please print this confirmation for your records.  
Further instructional information is  provided on the OPEN tab of the CTSU members‚Äô side 
of the CTSU website at https://www.ctsu.org or at https://open.ctsu.org . For any 
additional questions contact [CONTACT_862594] [ADDRESS_1202446] Information Form to Nutrition Shared Resource at UCSD 
at  and notify  via email at . 

CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202447] be offered to all 
patients enrolled on CALGB [ZIP_CODE] (although patients may opt not to participate). The substudy included within CALGB [ZIP_CODE] is CALGB 151105, ‚ÄúCarotenoid and polymorphism analysis  of patients enrolled to CALGB [ZIP_CODE].‚Äù This study does not require 
separate IRB approval.  
If a patient answers ‚Äúyes‚Äù to ‚ÄúI agree that my specimens may be used for the research described above,‚Äù (Question #1) in the Model Consent, he has consented to participate in the correlative science studies described in Sections 10.2, 10.3, and 10.4 . The patient 
should be pre- registered  to CALGB 151105 at the same time that he is pre- registered  to 
CALGB [ZIP_CODE] and in addition to collecting the required plasma for car otenoid and 
cholesterol testing;  whole blood , serum , and unstained slides should be collected per 
Section 6.2. Whole blood samples should be submitted at the time of pre- registration.  
5.[ADDRESS_1202448] two chances to successfully complete 
the run -in.  
5.5 Patient  Registration/Randomization  
Upon completion of the run- in, UCSD staff will notify the site and the study Data 
Coordinator about patient eligibi lity. Eligible patients who completed the run -in and 
consumed fewer than 6 servings of fruit and vegetables per day will then be registered and randomized by [CONTACT_779]. Patients who are determined to be ineligible for the study 
should be notified by [CONTACT_862595].  
Registration procedures:  
‚Ä¢ Site staff will need to be registered with CTEP and have a valid and active CTEP -IAM 
account. This is the same account (user id and password) used for the CTSU members' web site.  
‚Ä¢ To perform registrati ons, the site user must have been assigned the 'Registrar' role on 
the relevant Group or CTSU roster.  
The OPEN  system will provide the site with a printable confirmation of registration. Please 
print this confirmation for your records.  
Once the randomizat ion is complete , patients will be contact[CONTACT_862596]. Patients will also receive an enrollment packet, provided by [CONTACT_61207], which will contain the information al materials  described in Section 8.3 . 
5.6 Registration to companion study 151105  
If a patient answered  ‚Äúyes‚Äù to ‚ÄúI agree that my specimens may be used for the research 
studies described above.‚Äù (Question #1) in the Model Consent,  the patient should have 
been pre- registered to CALGB 15 1105 at the same time that he was pre -registered to 
[ZIP_CODE]. At this time, patients who were pre -registered to 15 1105 should be registered to 
the study and samples submitted per Section 6.2.  
5.7 Stratification Factors  
1. Age  
a) Men ‚â§ 70 years  b) Men > 70 years  
2. Race  
a) Black or African American  b) Other  
3. Baseline Prostate Biopsy  
a) 0-12 months prior to pre -
registration  b) > 12 -24 months prior to pre -registration  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
17 6.0 DATA  SUBMISSION  AND  SAMPLE  SUBMISSION  
6.1 Data Submission  
Forms should  be submitted to the Alliance Statistics and Data Center (SDC) in 
compliance with the Data Submission Schedule below.  
Forms must  be submitted electronically using the ‚ÄúSubmit to CALGB‚Äù button located at 
the bottom of the last page of each form. Any require d forms, supporting documentation 
or amended forms that cannot be submitted electronically should be mailed directly to 
the Alliance Data Center for scanning and quality review at the address below:  
Alliance Data Center  
 
 
 
 
For the most up -to-date forms, please visit the Alliance  or CTSU web site.  
  

CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
18  
Data Submission Schedule: 
 
Form  Submission Schedule  
 Pre-Registration  
 Pre-Registration Worksheet  Submit at pre-registration  
   
C-[ADDRESS_1202449] Information Form  Submit to UCSD staff (See Sec. 5.2 ) 
      Registration  
 Registration Worksheet  Submit within [ADDRESS_1202450] -P Form  Submit at 6, 12, 18 and 24 months  
   
C-2004 CALGB [ZIP_CODE] Nutritional Self Efficacy Form  Arm A patients only:  Submit at 6, 12, 
18 and 24 months  
   
C-2008 CALGB [ZIP_CODE] MEAL Study Counseling 
Evaluation Form  Arm A patients only:  Submit at [ADDRESS_1202451] Intervention Follow -Up 
C-2013 CALGB [ZIP_CODE] Follow Up Form  Submit every 3 months until 2 years 
from date of registration (see Section 
8.7) 
      Other  
C-260 CALGB Remarks Addenda  Submit as needed  
 
If a study participant chooses to withdraw from the study, submit the C -260 CALGB Remarks 
Addenda to the Alliance Data Center and copy by [CONTACT_6791]  
 
6.2 Sample Collection and Submission  
Histopathology review will be conducted using specimens from prostate biopsies. The 
submission of these samples for histopathology review is required for all patients 
registered to this stu dy.  

CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #[ADDRESS_1202452] ask patients for their consent for the use of 
serum , whole blood , and unstained slides  for the additional carotenoid and polymorphism 
analyses described in Sections 10.2 , 10.3 , and 10.4 (sub-study CALGB 151105).   
Submit slid es and blood samples as described below.  
 Pre-registration*  12 months ** 24 months ** Ship to:  
 Required for all patients registered to [ZIP_CODE]  
H&E slides  X  X OSU 
Plasma 
(Green top)  1 x 10 mL  1 x 10 mL  1 x 10 mL  OSU 
 Required for patients registered to [ZIP_CODE] and  
substudy 151105  
Serum  
(Red top)  1 x 10 mL  1 x 10 mL  1 x 10 mL  OSU 
Whole blood  
(Lavender top)  1 x 10 mL    OSU 
Unstained 
slides  X   OSU 
‚Ä¢ Pre-registration samples should be submitted within two weeks after the patient has been 
registered and randomized to the study ; except whole blood samples, which should be 
submitted on the same day as collection . If the patient does not complete the run -in, or is not 
registered/randomized to the study for any other reason, samples collected at pre- registration 
should be destroyed per institutional practice. The whole blood sample submitted at pre -
registration will be destroyed by [CONTACT_862597].  
** Blood s amples should be collected and submitted regardless of whether the patient has 
progressed or elected to receive therapy.  H & E slides at the 24- month time point are not 
required for patients who have started definitive treatment (e.g., prostatectomy or radiation 
therapy).  
USE OF THE ALLIANCE BIOSPECIMEN MANAGEMENT SYSTEM (BioMS) IS 
MANDATORY AND ALL SPECIMENS MUST BE LOGGED AND SHIPPED VIA THIS 
SYSTEM.  
BioMS is a web -based system for logging and tracking all biospecimens collected on 
Alliance trials.  Authorized individuals may access B ioMS at the following URL:  
http://bioms.allianceforclinicaltrialsinoncology.org using most standard web browsers 
(Safari, Firefox, Internet Explorer).  For information on using the BioMS system, please refer to the ‚ÄòHelp‚Äô links on the BioMS web page to access the on- line user manual, FAQs, 
and training videos.  To report technical problems, such as login issues or application errors, please contact: .  For assistance in 
using the application or questions or problems related to specific specimen logging, please 
contact:  
[CONTACT_711097], the system will create a shippi[INVESTIGATOR_452214].  
This shippi[INVESTIGATOR_862560].  
All submitted specimens must be labeled with the protocol number ([ZIP_CODE]), patient study ID number, patient‚Äôs initials and date and type of specimen collected (e.g., serum, whole 
blood). A copy of the Shipment Packing Slip produced by [CONTACT_862598].  

CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202453] be marked ‚ÄúFor 
Saturday delivery.‚Äù Do not ship specimens on Saturdays.  
All specimens should be sent to the following address:  
Alliance Biorepository at Ohio State University 
The Ohio State University  
Innovation Centre  
 
 
 
 
6.2.1  S
ubmission of H&E stained prostate biop sy slides (required for all patients)  
Pathology specimens will be collected with a minimum of [ADDRESS_1202454], extended biopsy pattern for confirmation of prostate pathology. 
Prostate biopsy slides will be subm itted at baselin e and 24 months.  
Additional biopsies:  If, at the discretion of the treating physician, a patient 
undergoes additional prostate biopsies at a time other than 24 months, the prostate biopsy slides from these additional prostate biopsies should be submitted as well.  
Representative stained hematoxylin and eosin (H&E) diagnostic slides from each 
biopsy site/container are to be submitted to the Alliance Biorepository at Ohio 
State University  for review.  The pre -registration sample should be from the initial 
biopsy showing diagnosis of cancer. Submission of paraffin embedded tissue blocks is 
not required. Submission of the local pathology report is required. The local pathology report should contain the number of cores obtained for each biopsy to allow central  
verification that ‚â• [ADDRESS_1202455] her  
evalua tion to the Alliance Statistics  and Data Center.  
If H&E stained slides are not available for submission, digital images may be 
submitted. Please contact  [CONTACT_862599].  
6.2.2  Plasma samples (required for all patients)  
Throughout all stages of blood processing, shippi[INVESTIGATOR_007], and handling, it is very 
important to prevent prolonged exposure of samples and separated blood components to light. Work quickly and efficiently. When samples and  sample components must be 
set aside, cover them or put them away from light.  
First prepare the vacutainer tubes for protection from light by [CONTACT_6406][INVESTIGATOR_862561] a red or amber colored specimen 
bag. 
Draw 10 mL of whole blood in a green top (heparin coagulant) tube and gently invert 
it once or twice to mix the additive with the blood. Immediately replace the tube into 
the previously prepared aluminum foil slip or place it into the red or amber colored 
specimen bag.  
Samples should be processed within 30 minutes of collection. If this is not possible, 
the tube(s) should be refrigerated until centrifugation. Before centrifugation, make sure the brake is off, the speed is set between 2,800 ‚Äì 3,000 rpm, the temperature is 
4¬∞ to 8¬∞ C and the centrifugation time is set at 10 minutes.  

CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
21 After centrifuging for 10 minutes, allow the centrifuge to come to a complete stop 
before opening the cover. Do not use the brake as it may cause the red blood cells to become re-suspended in the plasma. Any tube containing red blood cells in the 
plasma should be re- centrifuged. Immediately return the tubes to the light protection 
device (aluminum foil pouch or red or amber bag).  
The plasma should be aliquotted into cryovials* within [ADDRESS_1202456] the samples in the -70¬∞ C freezer as soon as possible after aliquotting. 
Samples must be frozen at least 2 hours before packing them for shipment.  If a -70 ¬∞ 
C freezer is not available, the cryovials can be stored in a  -20¬∞C freezer immediately 
after aliquotting, and then transferred to a -70¬∞  C freezer as soon as possible, but for 
no longer than 2 days (over the weekend). Placing the samples on wet ice or dry ice does not sufficiently preserve the sample; at least a -20¬∞ C freezer is required.  
Samples may NOT be thawed after freezing. See Section 6.2.4 for packing and 
shippi[INVESTIGATOR_3931].  
* Cryovial Choices: Some examples of acceptable 2.0 ml cryovials are: Nalgene (Cat 
#5012- 0020), Fisher (Cat #05-669- 57), Corning (Cat #430488), VWR (Cat 
#[ZIP_CODE]-102). 
6.2.3   Serum samples (required for patients enrolled to substudy 151105)  
Throughout all stages of blood processing, shippi[INVESTIGATOR_007], and handling, it is very important to prevent prolonged exposure of samples and separated blood components to light. Work quickly and efficiently. When samples and sample components must be set aside, cover them or put them away from light.  
First prepare t he vacutainer tubes for protection from light by [CONTACT_6406][INVESTIGATOR_862562] a red or amber colored specimen 
bag. 
Draw  [ADDRESS_1202457] it into the 
red or amber colored specimen bag.  
Samples should be processed within 30 minutes of collection.  If this is not possible, 
the tube(s) should be refrigerated until centrifugation. Before centrifugation, make 
sure the brake is off, the speed is set between 2,8 00 ‚Äì 3,000 rpm, the temperature is 
4¬∞ to 8¬∞ C and the centrifugation time is set at 10 minutes . 
Before you start the centrifugation, make sure the brake is off, the speed is set between 2,800 - 3,000 rpm, the temperature is 4- degrees C to 8 -degrees C and the 
centrifugation time is set at 10 minutes.  
After centrifuging for 10 minutes, allow the cen trifuge to come to a complete stop 
before opening the cover. Do not use the brake as it may cause the red blood cells to become re -suspended in the serum. Any tube containing red blood cells in the serum 
should be re- centrifuged. Immediately return the tubes to the light protection device 
(aluminum foil pouch or red or amber bag).  
The serum should be aliquotted into cryovials* within [ADDRESS_1202458] the samples in the -70¬∞ C freezer as soon as possible after aliquotting. 
Samples must be frozen at least 2 hours before packing them for shipment.  If a -70 ¬∞ 
C freezer is not available, the cryovials can be stored in a  -20¬∞C freezer immediately 
after aliqu otting, and then transferred to a -70¬∞ C freezer as soon as possible, but for 
no longer than 2 days (over the weekend).  Placing the samples on wet ice or dry ice does not sufficiently preserve the sample; at least a -20¬∞C freezer is required.  
Samples may NOT be thawed after freezing. See Section 6.2.4 for packing and 
shippi[INVESTIGATOR_3931].  
 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
22 * Cryovial Choices: Some examples of acceptable 2.0 ml cryovials are: Nalgene (Cat 
#5012- 0020), Fisher (Cat #05-669- 57), Corning (Cat #430488), VWR (Cat 
#[ZIP_CODE]-102). 
6.2.4  Packing and shippi[INVESTIGATOR_862563]  
(1) Place dry ice nuggets on the bottom of the insulated shippi[INVESTIGATOR_7788].  
(2) Place each freezer box in a sealed plastic bag. Remove as much air as possible 
from the bag before sealing.  
(3) Place the sealed bags in the insulated shippi[INVESTIGATOR_862564].  
(4) Layer additional* dry ice on top of and around the plastic bags. Place any remaining freezer boxes in sealed plastic bags on top of the dry ice.  
* Overnight deliveries should contain about 10- 12 pounds of dry ice. This will 
allow the package to remain frozen for 48 hours in case the shipment is delayed.  
(5) Seal the shippi[INVESTIGATOR_862565]. 
To delay thawing, place the box in the -70¬∞  C freezer to await pi[INVESTIGATOR_9107].  This step 
need not be done if the box is packed within 2- 3 hours of pi[INVESTIGATOR_9107].  
Ship specimens to:  
Alliance Biorepository at Ohio State University 
The Ohio State University   
Innovation Centre   
 
 
  
Shipment on Monday through Friday by [CONTACT_862600]. If shippi[INVESTIGATOR_711074], FedEx or UPS must be used and the air bill 
must be marked ‚ÄúFor Saturday delivery.‚Äù Do not ship specimens on  Saturdays. 
6.2.5  Whole blood (required for patients enrolled to substudy 151105)  
Draw 10 mL whole blood in a lavender top (EDTA coagulant) tube and keep 
refrigerated until shipped overnight to the Alliance Biorepository at Ohio State 
University . Label the tube with the patient‚Äôs initials, patient study  ID number, study 
number (CALGB  [ZIP_CODE]), and date of collection. The sample should be shipped the 
same day on a cold pack by [CONTACT_716744]:   
Alliance Biorepository at Ohio State University The Ohio State University   
Innovation Centre   
 
 
  
 
Shipment on Monday through Friday by [CONTACT_862600]. If shippi[INVESTIGATOR_711074], FedEx or UPS mu st be used and the air bill 
must be marked ‚ÄúFor Saturday delivery.‚Äù Do not ship specimens on  Saturdays. 
6.2.6  Submission of un stained diagnostic prostate biopsy slides (required for patients 
enrolled to substudy 151105) 
Submit ten , or as many  slides as con tain cancer, 5 ¬µm unstained sections on charged 
glass slides from the formalin- fixed, paraffin -embedded, diagnostic prostate biopsy 
blocks to the Alliance Biorepository at The Ohio State University (see Section 6.2). 
Label the slides with patient study ID number, accession number, and order of 
sections.   

CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
23 7.0 REQUIRED  DATA   
Guidelines for Pre- Study Testing  
To be completed within 3 months before preregistration  
- Baseline PSA, history and physical, DRE  
To be completed within 24 months before preregistration  
 - Prostate Biopsy  
 Preregis -
tration  Run-
in Month * 
[ADDRESS_1202459] and Observations            
History and Physical X   X  X  X  X 
Height‚Ä†  X          
Weight‚Ä† X   X  X  X  X 
DRE X     PRN    PRN 
Diet Recall   A    A    A 
Labs and Staging            
PSA X  X X X X X X X X 
QOL Instruments            
Personal Habits 
Questionnaire  B          
MAX-PC B   X  X  X  X 
Nutritional Self -Efficacy  B   D  D  D  D 
I-PSS B   X  X  X  X 
EPIC-[ADDRESS_1202460] -P B   X  X  X  X 
MEAL Counseling 
Evaluation       D    D 
Sample Submission            
Plasma for Carotenoid 
Analysis  C     X    X 
H & E  biopsy slides‚Ä°  C         X(1) 
Correlative Study  
See Section 6.2.  Serum  
Whole Blood  
Unstained Slides ‚Ä° 
A To be conducted by [CONTACT_662412].  
B To be administered to all patients at the pre -registration visit and submitted after the patient is 
registered to the study.  
C To be collected for all patients at the pre -registration visit and submitted after the patient is 
registered to the study.  
D To be administered to patients randomized to Arm A only.  
* Clinic visits may be done within +/ - 2 weeks of the scheduled 3- , 6-, 9-, etc. month visit.  These visits 
are to be scheduled from the date of randomization.  
‚Ä† Refer to Section 8.1 for height and weigh t measurement instructions.  
‚Ä° Slides should be from the initial biopsy showing diagnosis of cancer.  
[ADDRESS_1202461] started definitive treatment (e.g., 
prostatectomy or radiation therapy) . 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202462] information and QOL assessments: At preregistration participants will 
complete the C -2010, MEAL Participant Contact [CONTACT_130052]. This form is to be 
faxed by [CONTACT_862601] 24 hours of preregistration.  
All patients will be asked to complete the QOL instruments listed in S ection 7.0. 
These forms should be submitted to the Alliance Statistics and Data Center  after the 
run-in period and within 2 weeks of registration.  
8.1.2  Blood sample collection: In addition, all patients will be asked to provide a 6- hour 
fasting blood sample for carotenoid and ch olesterol analysis. This sample should not 
be submitted until within 2 weeks after registration.  
8.1.3  Clinical assessments  
Urologic assessment:  At initial assessment, participants will be evaluated in a 
urology clinic as per typi[INVESTIGATOR_19529] l AS protocols and current standard of care (2 -4, 11, 13). 
Urological evaluations will be conducted by [CONTACT_862602]. The baseline visit will include a DRE to confirm clinical stage. DRE will entail palpation of t he posterior and posterolateral aspects of the entire 
prostate in the standard fashion.  
Height and weight  must be obtained during preregistration. Below are recommended 
guidelines to obtain these measurements in an accurate manner.  
Height:  Measure the participant‚Äôs height without shoes, using a stadiometer. Ask 
participant to stand up with heels together and weight equally distributed. Ideally, participants heels, buttocks, shoulders, and head should all touch the vertical board; however, in some cases this may not be possible. In this event, take the measurement 
with buttocks and heels touching the vertical board, or with head and buttocks touching the vertical board. Ask the participant to breath in deeply at which juncture the movable headboard should be placed on the head with only enough pressure to 
slightly compress the hair. Record height to the nearest 0.25 inch, rounding down.  
Weight:  Weigh each participant on a medical balance or electronic scale in light 
clothing without shoes. Each participant should be weighed on the same scale 
throughout the study. Place the scale on a level uncarpeted floor surface. Before each weighing, check the scale to confirm that it reads zero in the absence of a load, and if necessary adjust it to read zero. If the participant‚Äôs feet are bare, one may place a disposable paper towel on the scale platform. Ask the participant to stand still on the scale platform, arms down at their sides, and feet centered on the platform with 
weight evenly distributed. Record weight to the nearest pound.  
8.2 Run-In 
Eligible patients will be contact[CONTACT_862603] a week to schedule a series of three 24 -hour dietary recalls which will be completed within 3 weeks.  
8.3 Registration/Randomization  
Upon completion of the run- in, UCSD staf f will notify the site and the study Data 
Coordinator about patient eligibility. Eligible patients who successfully completed the 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
25 run-in and consumed fewer than 6 servings of fruits and vegetables (not including juices) 
per day will then be randomized.  
After randomization, all patients will participate in a 5-10 minute telephone orientation 
conducted by [CONTACT_862604] -related events. The orientatio n call for intervention 
participants randomized to Arm A will briefly explain the counseling program, the dietary targets, and the scientific rationale supporting these targets. The UCSD study staff will mail all participants (Arm A and Arm B) a copy of the Prostate Cancer Foundation  Booklet 
entitled ‚ÄúNutrition, Exercise and Prostate Cancer.‚Äù In addition, participants randomized to the counseling intervention (Arm A) will also be mailed a copy of the study- specific 
‚ÄúLifestyle Intervention Manual‚Äù which will be referred to during every  counseling call. The 
manual outlines the dietary targets, offers supporting information on strategies to achieve 
these targets, supplies reference tools to help participants accurately estimate servings of 
target foods, and offers recipes and articles abo ut diet and prostate cancer.  
All counseling will be performed by [CONTACT_862605] a counseling program and infrastructure of personnel developed during the WHEL (68) and MEAL (40, 42) studies. The protocol will follow a s tep-wise, phased approach 
employing strategies adopted from social cognitive theory. Motivational interviewing techniques will be utilized to help patients maintain responsibility for their own behavior 
change.  
Each participant in Arm A will be assigned to  a personal counselor/coach; if the 
participant has a spouse or significant other, the counselor/coach will also seek to enlist 
his or her cooperation and support. Counselors will work morning, afternoon, or evening shifts, and every effort will be made to  assign participants to a counselor working when 
they prefer to receive calls. Call length will range from 20 -40 minutes. Calls will be more 
frequent and of longer duration during the early phases of counseling.  
Educational materials  will be sent to patients on a schedule that supports the 
behavioral intervention goals.  
The Lifestyle Intervention Manual  that patients enrolled to Arm A receive will include 
background material on dietary targets, as well as monitoring forms that patients can use 
to monitor th eir dietary change.  
Newsletters: In order to maintain participant morale, UCSD staff will develop eight 
newsletters for participants on both arms of the study. Each newsletter will be four pages 
and will contain information about diet and healthy lifestyle, as well as diet and cancer. Recipes will also be included in these newsletters. The content of the first three pages of 
the newsletters will be nearly identical. The fourth page of the newsletters, which will 
provide recipes to participants, will vary b y group.  
These newsletters will be distributed to participants by [CONTACT_862606]  (quarterly) . Electronic versions of the newsletters will be made available on the 
Alliance  and the CTSU Web sites. Institutions must receive IRB approval of these 
newsletters prior to their distribution to patients. Care should be taken to ensure that 
patients receive the newsletter tailored to the arm to which they are randomized.  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202463] quarter of 2012 should receive the newsletter entitled ‚Äú Comfort Foods ‚Äù as their first newsletter while on study . The planned 
distribution schedule is as follows:  
Number  Topic  Distributed 
to study 
participants   Number  Topic  Distributed 
to study 
participants  
1 Portion 
Control  July-Sept. 
2011  1 Portion 
Control  July-Sept. 
2013 
2 Quick & Easy  Oct.-Dec. 
2011  2 Quick & Easy Oct.-Dec. 
[ADDRESS_1202464].-Dec. 
2014 
7 Solo Suppers  Jan.-Mar. 
2013  7 Solo Suppers  Jan.-Mar. 
2015 
8 Cheap Eats  Apr.-June  
2013  8 Cheap Eats  Apr.-June  
2015 
8.4 Clinic Visits  
PSA Measures (Every 3 Months)  
Serum PSA levels will be measured at baseline and at every 3 months thereafter. PSADT will be calculated as log2 divided by [CONTACT_704479] (the least squares estimator) of log (PSA) observations over time using the last three PSA measurements (44, 83, 100). An example 
of a PSADT calculator can be found at www.ASU RE.ca.  
History & Physical  (Every 6  Months)  
Participants will be evaluated in a urology clinic at initial assessment and every [ADDRESS_1202465] of care (2- 4, 11, 13). Patients 
must be weighed and their height measured according to the instructions in Section 8.1. 
Urological evaluations will be conducted by [CONTACT_862607] (e.g., medical oncologist, PA, NP) at each site. The baseline visit will include a DRE to 
confirm clinical st age. Since PSA and biopsy changes are much more sensitive for 
detecting clinical progression than changes in prostate examination among patients on AS (11), subsequent DRE will be performed at the discretion of the individual urologist. 
These results will not be used to define progression.  
Prostate Biopsy (24 Months)  
Prostate biopsy will be performed by [CONTACT_862608] [ADDRESS_1202466] the right to secure a biopsy earlier than 24 months. Although DRE is commonly used in oncologic practice, it is not highly quantifiable for men with the ve ry 
small, often non -palpable tumors of our study participants.  
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
27 Blood Sample Submission (12, 24 Months)   
Six-hour fasting b lood samples will be collected at preregistration, 12 and 24 months and 
will be submitted to the Alliance Biorepository at Ohio State University  (see Section 6.2.1) 
and analyzed for carotenoid and cholesterol concentrations.  
Quality of Life Instruments (Every 6 Months)  
Seven quality of life measures will be used: Personal Habits Questionnaire will be 
completed at pre- registration only, t he Functional Assessment of Cancer Therapy Scale-
Prostate (FACT -P); Memorial Anxiety Scale for Prostate Cancer (Max -PC); International 
Prostate Symptom Score (IPSS); Expanded Prostate Cancer Index Composite 26 (EPIC -
26); and the Nutrition Self ‚ÄìEfficacy will be completed at preregistration and every 6 
months. Finally, the MEAL Study Counseling Evaluation Form will be completed at 12 
and 24 months (see Section 9.0).  
8.[ADDRESS_1202467] approximately 20 minutes. 
Patient recalls will be performed on three randomly selected days over a three- week 
period and include two weekdays (Monday through Thursday) and one weekend (Friday through Sunday). Data will be catalogued and analyzed utilizing Minnesota Nutrition 
Data System (NDS) software (Nutrition Coordinating Center, University of Minnesota).  
8.6 Telephone Counseling Intervention (Arm A Only)  
The counseling intervention will be divided into four phases, with the first three phases 
completed in 7 months. The fourth phase will continue for 17 months. Each counseling 
call will take an average of 30 minutes.  
Phase I: The first phase, composed of six counseling calls, will focus on education and 
the rapid development of self -efficacy skills. During this phase, frequent counseling 
sessions (every 3- 4 days) will focus on short -term goals, emphasizing to participants and 
partners that the study dietary pattern can be compatible with their lifestyle. The 
counselor will monitor self -reported dietary intake interactively using dietary analysis 
software (The Food Processor for Windows, Version 7.8, ESHA Research, Salem, OR) to help the participant evaluate his performance and encourage him to concentrate on the positive aspects of his achievements before setting new sub -goals. Throughout this phase 
(and all other phases), counselors will encourag e participants to report any difficulties in 
adopting the dietary pattern, and dietary targets will be adjusted accordingly to maximize 
chances of success.  
Phase 2:  The second phase, composed of four calls over a 2 -month period, will focus on 
practical an d consistent implementation of the dietary pattern. Counselors will help 
participants make structural changes to their food environments, such as altering the 
type of food available in the house, modifying recipes and patterns of food preparation, and focu sing on portion sizes. Participants will learn to monitor their performance 
regularly, as counselors encourage goal setting and review.  
Phase 3:  The third phase, composed of four calls over a [ADDRESS_1202468] in behavior 
maintenance, even as the level of necessary social guidance declines.  
Phase 4:  The counselors will regularly check on progress (8 calls over a 17 -month 
period), providing positive feedback on achievements in maintain ing the study targets 
while monitoring for warning signs of declining interest or self -efficacy. Ensuring 
participants that they can maintain the change they have implemented will still be 
critical. Intervention contacts will take place once every other mo nth by [CONTACT_862609] A 
only. 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
28 Dietary Targets:  Participants in the intervention arm will be encouraged to achieve a 
challenging but attainable dietary pattern: 7 servings per day of vegetables (2 cruciferous, 
2 tomato products, 3 other vegetables), [ADDRESS_1202469] bioactive nutrients and phytochemicals, intervention participants will be instructed to omit fruit jui ce, iceberg lettuce, and white potatoes from 
their calculations of plant vegetable and fruit servings. Counselor/coaches will emphasize colorful vegetables along with strong -flavored produce (cruciferous vegetables, onions, 
garlic), since strong flavor is an indicator (albeit crude) of phytochemical concentration.  
Within the context of these overall dietary targets, participants will be guided to obtain an 
adequate intake of all essential nutrients.  
8.6.[ADDRESS_1202470] 
coaching session. This training will be overseen by [CONTACT_862610]; the team has been involved in a multitude of behavior change studies.  
We have developed a detailed, relational database that provides counselors with a 
computer -assisted coaching protocol for their participant contacts.  All contacts will be 
recorded in the database, and the database will generate the call schedule for each counselor each day. Calls will then follow a script that includes suggested question 
phrasing and responses to key questions inserted into the databas e in real time; 
these standardize intervention delivery. Automatic range checks will ensure quality in 
the dataset. At the completion of each call, the counselor will be prompted for detailed comments that can be used in the next contact. These comments will be reviewed by [CONTACT_862611] a component of performance review. Each counselor‚Äôs performance will be compared to that of his or her peers, in terms of achieving dietary change 
toward study goals and in keepi[INVESTIGATOR_862566].  
The database will provide weekly management reports to focus on key aspects of 
study progress, including delinquent data collection. The database will help us monitor regularly scheduled study operations, to comply with aspects of the protocol. For example, study reports will be generated, as needed, to identify intervention participants who have not been contact[CONTACT_862612]. The reports will be provided to the counselors to help keep them on schedule, and to ensure that participants with lagging performance or possibly lagging interest do not drop out of 
the study.  
To maximize effectiveness of the intervention, we will seek participant permission, in 
advance, to monitor calls. We will then monitor 10% of calls. The calls will be audio -
taped and reviewed by [CONTACT_862613]. Throughout the study period, weekly case -
management sessions will be conducted; supervisors, study investigators and 
counselors will use these to resolve challenging issues that have emerged.  
A registered dietitian will supervise the telephone counseling intervention team. 
Counselors will also attend monthly 2 -hour meetings, which will include updates on 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
29 study progress and in -service training on nutrition and be havior change counseling. 
On a quarterly basis, counselors will be provided with an assessment of their 
caseload‚Äôs adherence to the dietary targets as a means of maintaining or improving performance. Together, these procedures, have contributed to the success of the 
WHEL (68) and MEAL (40 -42) interventions.  
8.7 Completion of Intervention  
All patients are expected to participate in the diet intervention for 24 months.  
8.7.1  Off Treatment Criteria  
Off-Treatment criteria will include the following: 1) physic ian determination that 
continuation of the diet is medically contraindicated, 2) participant decision to 
withdraw from the dietary intervention, or 3) participant death. If a study participant chooses to withdraw from the study, submit the C -[ADDRESS_1202471] in this prevention trial is disease progression defined by (a) PSA doubling time (PSADT) less than 3 years, (b) PSA above 10 at any time, or (c) Gleason score on repeat biopsy ‚â• 7 for men younger than 70 years and ‚â• 4+3 = [ADDRESS_1202472] active 
surveillance studies to date, the Toronto cohort (12).  
Participants who do not meet PSA or biopsy criteria for progression are strongly 
encouraged to remain on AS while in the study and not undergo treatment with surgery, radiation, local ablation, or androgen deprivation. The se criteria reflect the 
current standard of care (11,12) and are as follows:  
a) PSA doubling time (PSADT) < 3 years  
b) PSA ‚â• 10 ng/mL  
If the treating physician suspects that a single measurement of PSA ‚â• 10 ng/mL 
represents a spurious rise unrelated to cancer progression (e.g., clinical prostatitis , asymptomatic prostatitis in association with a viral syndrome,  or 
instrumentation of the urinary/gastrointestinal tracts), a repeat PSA may be drawn up to 2 w eeks later. If the repeat PSA value is less than 10 ng/mL, then 
that repeat PSA value shall be recorded for that visit. If the repeat PSA value ‚â• 10 
ng/mL, the first PSA value should be recorded for that visit.  
c) Repeat biopsy  
o ‚â• 25% of biopsy tissue cores positive for cancer  
o > 50% of any one biopsy tissue core positive for cancer  
o Men < 70 years at baseline:  Gleason sum ‚â• 7 
o Men ‚â• 70 years at baseline:  Gleason sum ‚â• 4+3 = [ADDRESS_1202473] to pursue treatment during the study 
despi[INVESTIGATOR_862567]. These participants will be censored 
at the time they begin treatment.  
8.7.3  Continuation of the Dietary Intervention  
Patients should continue intervention and follow -up for the two -year duration of the  
study regardless of progression or electing to receive therapy.  
9.0 OUTCOMES
 ASSESSMENT/QUALITY  OF LIFE  MEASURES  
Seven quality of life measures will be used: Personal Habits Questionnaire, Functional 
Assessment of Cancer Therapy Scale- Prostate (FACT -P); M emorial Anxiety Scale for Prostate 
Cancer (Max -PC); International Prostate Symptom Score (IPSS); Expanded Prostate Cancer 
Index Composite 26 (EPIC -26); Nutrition Self ‚ÄìEfficacy and Satisfaction with the MEAL 
Program.  

CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
30 9.1 Personal Habits Questionnaire 
The personal habits questionnaire, used in the Women‚Äôs Health Initiative (WHEL) study 
(66), consists of 8 sets of questions that address a number of generic health behavior 
questions: cigarette smoking; alcohol consumption; weight change during adult life; adherence to any kind of special diet (e.g. low -calorie, low -fat, low -cholesterol, low salt, 
high-fiber); recreational physical activity, including mild, moderate and strenuous 
activity; and physical activity at various ages. These questions, which will be us ed mainly 
to make sure randomization produced comparable groups, are as appropriate for men as 
for women.  
9.2 Functional Assessment of Cancer Therapy Scale -Prostate [FACT- P] 
The FACT- P [version 4.0], developed by [CONTACT_253106] (44, 51) is a prostate  cancer 
specific quality of life questionnaire which includes a 27 item 'core' quality of life measure 
[FACT -G] grouped into four subscales: physical well -being, social/family well- being, 
emotional well -being, and functional well- being. There are an additional [ADDRESS_1202474] -P subscale items are rated on a 5 item Likert scale, from 0, 'not at all' to 4, 'very 
much'. The FACT -G has been tested on 630 patients w ith mixed cancer diagnoses. The 
internal consistency of the subscales ranges from .65 -.82, with excellent internal 
consistency of the total score: an alpha coefficient of .89. Test -retest reliability is excellent 
within a [ADDRESS_1202475] correlating significantly with other quality of life measures (FLIC, r=.79), and related constructs of psychological distress (e.g. Brief POMS, r=-.68) and the ECOG performance ra ting (r= -.52). The FACT -G has been able to 
distinguish between patients with metastatic and non -metastatic disease. Internal 
consistency of the Prostate- Specific Concerns subscale was of moderate strength (alpha 
coefficients ranging from .65 -.69] when test ed with 130 prostate cancer patients (44). 
Evidence of convergent validity of the Prostate- Specific Concerns subscale was provided 
by [CONTACT_862614] (Inventory to Diagnose Depression, r= -.34, p< .001), and anxiety (S pi[INVESTIGATOR_566034], r= - .33, p< .001). Further, 
significantly greater Prostate -Specific Concerns scores were found for those with more 
advanced disease than those with earlier stage disease. Sensitivity to change over time 
was also demonstrated  by [CONTACT_862615]-being, and Prostate- Specific Concerns subscale scores over a two month period for 
those with worsening Performance Status (44).  
9.3 Memorial Anxiety Scale for Prostate Cancer [MAX -PC] 
The Memorial Anxiety Scale for Prostate Cancer [MAX -PC] is a prostate cancer -specific 
measure to assess patient anxiety due to prostate cancer, PSA tests and fears of 
recurrence (45, 46). It consists of 18 items: [ADDRESS_1202476] of Event Scale, including avoidant and intrusive thoughts about prostate cancer (48); 3 
items specific to PSA tests, and 4 items concerning fear of recurrence. The items are 
grouped into three subscales: Prostate Cancer Anxiety (PCA), PSA Anxiety, and Fear o f 
Recurrence. Fourteen items are rated on a four point Likert scale ranging from 'not at all' 
to 'often' and 4 items are rated on a Likert scale ranging from 'strongly agree' to 'strongly disagree'. Internal consistency for the total score is excellent (al pha coefficient = .89). The 
PCA and Fear of Recurrence also demonstrated strong internal consistency (PCA alpha coefficient = .90; Fear = .85) (45). Test -retest reliability is excellent for the total score and 
three subscales (.74 - .89).  The three factor  model was confirmed in a second study of 
the MAX -PC (46). Total scores correlated significantly with other measures of distress, 
including the HADS (r=.52, p< .0001) and the Distress Thermometer (r =.45, p< .0001). Significant correlations were also found  between changes in the MAX -PC score with 
changes in the HADS total score (r=.30, p< .0001). Further, there was a significant difference among four PSA change groups (i.e. steady, rising, falling and unstable) for the 
MAX-PC (p = .003), PCA (p = .045), and the Fear of Recurrence subscale (p= .0001).  
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #[ADDRESS_1202477] outcome variable and a potential benefit of 
the counseling intervention. Moreover, it is likely that the distribution of printed dietary guidelines and intermittent phone calls to monitor diet intake, would potentially diminish anxiety in the control group because it involves more attention than active surveillance 
patients normally receive as part of clinical care (72).  
9.4 International Prostate Symptom Score (IPSS)  
This is an [ADDRESS_1202478] symptoms. It includes questions encompassing incomplete bladder emptying, 
frequent urination, urgency, nocturia, intermittency, weak stream, straining, and quality 
of life related to urinary symptoms (73).  
There are robust data to suggest that prostate cancer patients on active surveillance 
experience significantly decreased urinary health relative to men without prostate cancer. In a cohort analysis of 6,000 community dwelling older men, we observed that compared to men without prostate cancer, men with prostate cancer on active surveillance (i.e. those who had not undergone treatment) reported a significantly diminished quality of life due to urinary symptoms (74). In addition, several published studies have noted that high vegetable diets and higher serum carotenoid concentration are associated with decreased 
urinary symptoms (75 -77). 
9.5 Expanded Prostate Cancer Composite Index 26 (EPIC -26) 
This instrument is an  abbreviated version of the Expanded Prostate Cancer Composite 
Index (EPIC). It contains [ADDRESS_1202479] health -related quality of life 
domains relevant to prostate cancer: urinary incontinence, urinary irritation/obstruction, 
bowel, sexual and vitality/hormonal. Each domain has function and other subdomains. All of the domains for EPIC -[ADDRESS_1202480] 
consistency and validity for measuring these important outcomes related to prostate 
cancer survivorship (78).  
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
32 9.6 Nutrition Self -Efficacy Scale 
The Nutrition Self -Efficacy scale assesses the degree to which individuals are confident 
that that they can control their  nutrition (79). The scale assesses perceived self -efficacy, 
the confidence in one‚Äôs ability to meet one‚Äôs goals, and copi[INVESTIGATOR_52497] -efficacy, defined as 
optimistic beliefs about one‚Äôs capability to deal with barriers that arise in plans. The scale 
consists o f 5 items rated on a 5 point Likert scale, ranging from ‚Äòvery confident‚Äô to ‚Äònot 
confident at all‚Äô. Internal consistency was excellent (alpha coefficient = .87, n= 1,722).  Evidence of validity was provided by [CONTACT_862616] (r =.34, p< .01) (80). Because quality of life or anxiety has not been formally evaluated in an AS population or in the setting of a randomized clinical trial among AS patients, a battery of scores will be assessed as e xploratory variables, with 
scores at each time point and changes in scores over time assessed between the intervention and control groups using student‚Äôs t -test and linear regression modeling.  
9.7 Satisfaction with the MEAL Program  
At 12 and 24 months, tho se in the MEAL arm of the study will be asked to complete a 
series of questions about their satisfaction with the MEAL program  (C-2008, CALGB 
[ZIP_CODE] MEAL Study Counseling Evaluation Form) . All but one question has been used in 
WHEL, (Women‚Äôs Healthy Eating and Living, the prior diet study on which this study is based). The MEAL Satisfaction Questionnaire, developed by [CONTACT_25715][INVESTIGATOR_862568], includes 26 items with all items rated on Likert scales, with response categories varying by [CONTACT_862617]. The following areas of satisfaction are assessed: satisfaction with 
the nutritional plan, counseling calls, the counselor, the time and frequency of the calls, 
expectations that the diet will help to prevent recurrence and improve their overall health, barriers in attaining the dietary goals, and the difficulty encountered in changing and maintaining their diet. Internal consistency meets acceptable standards for the satisfaction with their food intake for the different types of food (5 questions, alpha coeffic ient = .71), satisfaction with the counselor (9 items, alpha coefficient = .87), and 
near an acceptable standard for the [ADDRESS_1202481] been (alpha coefficient = .69).  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202482] been 
associated with decreased prostate cancer risk. An analysis of the Health Professionals Cohort observed a 21% lower prostate cancer incidence among those with the highest compared to the lowest lycopene intakes. Moreover, tho se with the 
highest frequencies of tomato and tomato- based product intake had up to a 35% 
risk reduction compared to those with the lowest intake (20). In a meta -analysis of 
[ADDRESS_1202483] intake (fifth quintile of intake) of raw tomatoes [Relative Risk (RR) 0.89, 95% 
CI 0.8 to 1.0] or cooked tomatoes (RR 0.81, 95% CI 0.71 to 0.92) had a modest reduction in prostate cancer risk (10). These investigators also noted that while lycopene consumption was not associated with prostate cancer risk (RR 0.99, 95% 
CI 0.93- 1.06), higher serum lycopene concentrations were associated with decreased 
risk (RR 0.85, 95% CI 0.75- 0.97) (81).  
Interest in the potential therapeutic benefits of lycopene and/ or tomatoes has led to 
a small number of clinical trials that have produced promising, yet preliminary, results. Stacewicz -Sapuntzakis and Bowen placed 32 patients with prostate cancer 
on tomato paste -rich diet, 3 weeks before their scheduled prostatectomy . The 
patients consumed 26.8 mg of lycopene per day, compared with their usual mean intake of 5 mg/day. These investigators noted significant reductions in serum PSA concentrations and increases in apoptotic index in the intervention group compared with th e controls (82). Similarly, Kucuk and colleagues randomized [ADDRESS_1202484] smaller tumors, less 
involvement of surgical margins, and less diffuse involvement of the prostate by [CONTACT_5019]-grade prostatic intraepi[INVESTIGATOR_28601] (83). Chen and colleagues observed in 
a radical prostatectomy model that men who consumed large amounts of tomato products prior to surgery had less oxidative damage in the prostate (30), while Barber and colleagues noted decreased PSA velocities in men with prostate cancer 
treated with lycopene supplementation (25).  
While these data are compelling, associations of carotenoids with prostate cancer 
remain unclear. In the MEAL pi[INVESTIGATOR_799], there was no significant association of 
plasma lycopene or other carotenoids with plasma PSA over a 6- month period for AS 
patients or patients with PSA -only recurrence following surgery or radiation (40 -42). 
10.1.2  Objectives  
[IP_ADDRESS]  To compare plasma carotenoid concentrations in AS patients receiving dietary intervention compared to no intervention.  
[IP_ADDRESS]  To correlate plasma carotenoid concentrations with PSADT in AS patients.  
[IP_ADDRESS]  To correlate plasma carotenoid concentrations with time to pathological progression in AS patients.  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
34 10.1.3  Methods  
Carotenoids: The blood nutrient analysis will take place at UCSD under the 
direction of  The carotenoid analysis will be done at UCSD. Plasma 
carotenoids will be separated and quantified using the HPLC methodology that we 
have used previously (40, 67, 68), with modifications to reduce oxidative loss and improve recovery of compounds during analysis. Standard reference materials from the manufacturer will be used to validate analytical precision of these procedures. At UCSD, samples will be stored at all times at - 70¬∫ C or lower temperatures in freezers 
equipped with temperature alarms in the Moores UCSD Cancer Center that are 
under the direct supervision of .  
Cholesterol  is analyzed using the KODAK EKTACHEM DT SLIDE. The slide is a 
multilayered film in a plastic support. It contains all the reagents necessary to 
determine cholesterol level in serum or plasma. A 10 uL drop of specimen is deposited on the slide. The sample spreads evenly and diffuses into the reagent layers.  Cholesterol in the sample undergoes a series of reactions in the slide to 
produce a colored compound. The intensity of the color ids proportional to the amount of cholesterol in the sample and is measur ed by [CONTACT_862618]60 analyzer.  
Principles of the procedure: The spreading layer distributes the sample evenly on the slide and causes the cholesterol to dissociate from lipoprotein carriers. Cholesterol esters are hydrolyzed to free cholesterol which then undergoes a series of reactions beginning with oxidation by [CONTACT_862619], cholesterol oxidase. In the final reaction, a colored dye is produced. By [CONTACT_862620] a fixed incubation period,  the DT60 Analyzer can calculate the 
amount of cholesterol present in the sample.  
10.2 Serum carotenoid analyses (Substudy 151105)  
Carotenoid analysis can be evaluated on plasma or serum. Therefore, in addition to the plasma sample, we will be collecting a nd banking serum for evaluation of carotenoids, if 
needed, as well as for the evaluation of other circulating markers of interest.  
10.3 Polymorphism Analysis (Substudy 151105)  
10.3.[ADDRESS_1202485] been identified which are linke d to increase risk of 
developi[INVESTIGATOR_862569] (84 -89). There is increasing evidence that genetic 
factors could not only predispose men to prostate cancer in general but specifically for aggressive disease. For example CASP8 and MDM2 contain variants associated with risk of aggressive prostate carcinoma
 (90, 91) . Cheng et al (92) and Beebe -
Dimmer et al (93) demonstrated that at least some 8q24 variants are associated with 
risk of advanced disease. Duggan et al identified rs1571801, located in the  DAB2IP 
gene, as a candidate which was associated with aggressive PCa in both European-Americans (p=0.004) and African -Americans (p=0.02) (94). Mononen et al found that 
5‚Äô untranslated variant in CYP17A1 was associated with an increased risk of high 
grade PCa
 (95).  
Identification of a population of patients at risk for aggressive disease is only useful 
if the disease can be prevented or treated effectively. Dietary manipulation holds promise as a way of preventing or ameliorating the risk of developi[INVESTIGATOR_862570]. There is a growing body of evidence that dietary factors may modify 
genetic risk. Several genes, such as MnSOD, XRCC1, and GST , may modify the 
association of specific nutrients and foods with prostate cancer risk and groups have called for further research to confirm these initial observations (96). For example, 
evidence from the Physicians Health Study suggests that manganese superoxide 
dismutase ( MnSOD ) polymorphism V16A may interact with selenium levels to modify 
risk of clinically aggressive PCa
 (97). MnSOD  genotype were not associated with 
increased risk of disease. However, when they stratified the cases by [CONTACT_862621] [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202486] risk of developi[INVESTIGATOR_862571] (98). Given that vitamin D oral formulations have been explored as a treatment option for PCa (99), identification of an interaction between genotype 
and environment could have potential clinical application.  
The MEAL study offers the ideal population to study the interaction between genetic 
risk and diet.  First and foremost, if genetic risk is associated with aggressive disease, 
then patients with the high risk genetic background should be more likely to progress. What is unique about the MEAL study is to determine if dietary 
modification alters that genetic risk. If it does then genetically high risk patients 
could modify their diet at the time of diagnosis or possibly sooner. Alternatively, if diet does not modify risk of progression then more aggressive management could be 
instituted. 
10.3.2  Objectives  
[IP_ADDRESS]  To compare MnSOD, XRCC1, and GST gene polymorphisms to PSADT in AS 
patients receiving dietary intervention versus no intervention.  
[IP_ADDRESS]  To compare MnSOD, XRCC1, and GST gene polymorphisms to time to 
pathological progression in AS patients receiving dietary intervention versus no intervention.  
10.3.[ADDRESS_1202487] on the prostate such as 
catechol -o-methyl transferase and glutathione peroxidase.  
10.4 Analysis of diagnostic prostate biopsy sections (Substudy 1511 05) 
10.4.1  Background  
A great deal of information is contained in the prostate tissue in the diagnostic 
biopsy: the Gleason score, which indicates the aggressiveness of the cancer, and the size and location of t he cancer. Higher Gleason score and  larger tumor are associated 
with disease progression. The biopsy tissue can be used to describe the rates at which prostate cells are proliferating and at which prostate cells are undergoing apoptosis. 
Together, these factors provide an indicator of overa ll tumor growth index, which is 
associated with disease progression. The biopsy also can be used to describe the degree to which androgen- signaling proteins, including the androgen receptor, and 
androgen metabolism enzymes, including [ADDRESS_1202488] been linked to prostate cancer risk and 
to treatment outcome, with androgen signaling generally associated with the presence or development of more aggressive disease ( 108-110). Recent advances make possible 
the detection of small noncoding segments of RNA, known as microRNA, which can be extracted from serum and from tissue fragments. MicroRNAs [ADDRESS_1202489] received a great deal of attention as likely predictors of prostate cancer treatment outcome, will be examined in this study ( 111, 112) . These two microRNAs 
have been associated with more aggressive disease and with tumor progression.  
Taking these key indicators into account in analyses may enable better description of the likelihood that the prostate will respond to dietary change. Although randomized assignment should greatly lessen the likelihood of confounding of outcome by [CONTACT_862622] [ZIP_CODE]  
Version Date 09/26/18 Update #10  
36 baseline characteristics as tumor growth, proteins predictive of outcome, or 
microRNA;  taking these charac teristics into account may increase the power of these 
analyses. In addition, it is possible that these factors may interact with treatment 
assignment to affect cancer progression.    
10.4.2 Objectives  
[IP_ADDRESS]  To compare proliferation, apoptosis and the tumor growth index to dietary 
intervention assignment as predictors of cancer progression in AS patients.  
[IP_ADDRESS]  To compare proliferation, apoptosis and tumor growth index to outcome 
predictors among AS patients randomized to dietary intervention as opposed 
to those assigned to the comparison group.  
[IP_ADDRESS]  To compare protein levels of the androgen receptor and 5 -alpha reductase 1, 
2, and 3 to dietary intervention assignment as predictors of cancer progression in AS patients.  
[IP_ADDRESS]  To compare protein  levels of the androgen receptor and 5 -alpha reductase 1, 
2, and 3 as outcome predictors among AS patients randomized to dietary intervention as opposed to those assigned to the comparison group.  
[IP_ADDRESS]  To compare expression of microRNAs 141 and 375 to d ietary intervention 
assignment as predictors of cancer progression in AS patients.  
[IP_ADDRESS]  To compare expression of microRNAs 141 and 375 as outcome predictors 
among AS patients randomized to dietary intervention as opposed to those 
assigned to the compa rison group.  
10.4.3  Methods  
Institutions will be asked to provide 10 x 5 um unstained sections that show cancer 
on charged glass slides from the formalin -fixed, paraffin -embedded, diagnostic 
prostate biopsy blocks to the Alliance Biorepository at The Ohio State University (see Section 6.2). Only one core should be placed on each slide. Label the slides with CALGB [ZIP_CODE] patient ID number, accession  number, and order of sections.  
The immunohistochemistry will be pe rformed at  Roswell Park Cancer I nstitute, under 
the direction of . Commercially available antibodies will be used to 
immunostain the slides for the following:  Ki- 67 (proliferation), cleaved caspase 3 
(apoptosis), androgen receptor, and 5- alpha reduc tases 1, 2, and 3. A panel of 
microRNAs will be extracted from the serum collected as part of sub -study CALGB 
151105 (see Section  6.2.3). microRNA 141 and 375 expression will be assayed by 
[CONTACT_862623] (Blondal et al, 2013).  
10.4.4  Statistical considerations  
The baseline biomarkers will be associated with progression- free survival (PFS), time 
to progression as defined for the main study or death. Specific statistical analysis plans are as follows for each study objective. Abou t 80% of the patients in the main 
study will participate in this correlative study. With n= 334 (=418x0.8) patients, a Cox regression model to regress PFS on a continuous biomarker will have 95% of power to 
detect a log -hazard ratio (or, regression coefficient of the Cox proportional hazards 
model) of 0.[ADDRESS_1202490] with a two -sided alpha level of 5%. This power calculation is based on 
85% of 2 -year PFS for the whole population, the accrua l and follow -up periods 
assumed for the main study and the assumption that each marker is normally 
distributed (possibly after a transformation).  
[IP_ADDRESS]  To compare proliferation, apoptosis and the tumor growth index to 
dietary intervention assignment as predictors of cancer progression in AS patients  

CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
37 PFS will be regressed on each biomarker of proliferation ( KI-67), apoptosis (cleaved 
caspase 3) and tumor growth rate (a composite of proliferation and apoptosis ) using 
a Cox regression model. In order to see which biomarker s are independently 
prognostic, we will also perform a Cox regression to regress PFS on all three of the 
biomarkers.  We will repeat these regression analyses adjusting for treatment 
allocation to investigate if the effect of these biomarker s is confounded with 
treatment allocation.   
[IP_ADDRESS]  To compare proliferation, apoptosis and tumor growth index to outcome 
predictors among AS patients randomized to dietary intervention as opposed 
to those a ssigned to the comparison group  
The analyses adjusting for treatment allocation as described in in Section [IP_ADDRESS]  
will be repeated by [CONTACT_862624]. If any of these interaction terms are significant, then we will also fit a regression model within each arm to develop a prediction 
model based on the biomarkers for each treatment arm.    
[IP_ADDRESS]  To compare protein levels of the androgen receptor and [ADDRESS_1202491] of the biomarkers is confounded with treatment allocation.   
[IP_ADDRESS]  To compare protein levels of the androgen receptor and 5 -alpha 
reductase 1, 2, and 3 as outcome predictors among AS patients randomized  to 
dietary intervention as opposed to those a ssigned to the comparison group  
The analyses adjusting for treatment allocation as described in in Section [IP_ADDRESS]  
will be repeated by [CONTACT_862624]. If any  interaction terms are significant, then we 
will fit a regression model within each arm to develop a prediction model based on 
the biomarkers for each treatment arm.  
[IP_ADDRESS]  To compare expression of microRNAs [ADDRESS_1202492] of these biomarkers is confounded with 
treatment allocation.  
The microRNA package we are going to use will examine many more (~200) microRNA biomarkers.  We will develop a prediction model for PFS using all the 
examined microRNA biomarkers as candidate predictors using the gradient lasso procedure, 113 and compare the prediction power of this model with that based on 
microRNAs 141 and 375.  A Cox regression will be conducted including the risk 
score fitted using the gradient lasso method and treatment allocation.  
[IP_ADDRESS]  To compare expression of microRNAs 141 and 375 as outcome 
predictors among AS patients randomized to dietary intervention as opposed 
to th ose a ssigned to the comparison group  
The analyses adjusting for treatment allocation as described  in Section [IP_ADDRESS]  will 
be repeated by [CONTACT_862625] [ZIP_CODE] 
Version Date 09/26/18 Update #10  
38 between the two treatment arms. If any interaction terms are significant, then we 
will fit a regression model within each arm to develop a prediction model based on 
the biomarkers for each treatment arm.  
In order to inves tigate the prediction power of the fitted model using the gradient 
lasso in Section [IP_ADDRESS], a  Cox regression will be conducted including the risk 
score fitted using the gradient lasso  method,  treatment allocation and their 
interaction term . 
11.0 STATISTI CAL  CONSIDERATIONS   
11.1 Randomization  
Patients will be randomized with equal probability to receive the dietary intervention 
(experimental arm) or dietary information (control arm). A total of 464 patients will be enrolled to this trial, 232 patients per arm. The study will take a total of 5 years: about 3 
years of accrual with an expected accrual rate of 15 patients per month, and 2 years of 
follow -up for each patient.  
Stratification factors: Randomization will be stratified by [CONTACT_654] (‚â§  70 years  vs. > 70 years ), 
race (African American vs. Other) and baseline prostate biopsy (0 -12 months prior to 
registration vs. >12 -24 months prior to registration).  
11.[ADDRESS_1202493] in this prevention trial is disease progression defined by (a) PSA doubling time (PSADT) < 3 years, (b) PSA ‚â• 10 at any time, or (c) Gleason sum on 
repeat b iopsy ‚â• 7 for men younger than 70 years and ‚â• 4+3 = [ADDRESS_1202494] active surveillance studies to date, the Toronto cohort (12). Data from this cohort indicate that approximately 20% of patients on active surveillance will progress by [CONTACT_91980]: 14% by [CONTACT_862626] 8%-10% 
by [CONTACT_333777].  
Thus, using the log -rank test with a two -sided Œ± = 5%, a sample size of 418 will provide 
80% power to detect a difference in progression rate (P GR) of 20% in the control and 10% 
in the experimental arm during 24 months of follow -up. Under the exponential 
distributions for the time to progression, the 2- year PGR of 20% vs. 10% corresponds to a 
hazard ratio (HR) of 2.118. Assuming 10% of dropout rate (including patients who are treated before progression), a total of [ADDRESS_1202495] 50 
patients. From an analysis of grading by [CONTACT_862627].  Johns Hopkins pathologists, 
Gleason grading of adenocarcinoma in prostate needle biopsy tissue (106), Gleason score was changed from 3+4 by [CONTACT_862628] 4+3 by [CONTACT_862629] 14% of men and from 6 or below to 7 or above for about 8%  of men. Assuming about 30% 
of men in this study will be >70 years old and these two types of changes occur uniformly 
over the whole range of age, we believe that no more than 10% of men will become 
ineligible for the study by [CONTACT_862630]. We will consider increasing 
the sample size by a maximum of 10% depending on the proportion of men who become 
ineligible by [CONTACT_51723].  
11.3 Analysis  
The proportion of men who become ineligible by [CONTACT_862631]. The primary analysis will be done using data from eligible subjects, 
especially using Gleason scores from central review. However, all statistical analyses will be conducted for the data sets from eligible patients only, as well as all pat ients 
randomized in the sensitivity analysis.  
Progression:  PSADT will be calculated as log2 divided by [CONTACT_704479] (the least squares 
estimator) of log (PSA) observations over time using all available PSA measurements, starting from the time point at which we have three PSA measurements (i.e. the first 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
39 PSADT of a patient is calculated at month 6 using the PSA measurements collected at 
months 0, 3 and 6 if there are no missing PSA measurements .‚Äù In order to avoid any 
miscalculation, the PSADT will be calculate d at the Alliance Statistics and Data Center,  
not by [CONTACT_194674].  
Time to progression data will be analyzed using the log- rank test for univariable analysis 
and the Cox‚Äôs proportional hazards regression for multivariable analysis adjusting for th e 
stratification factors and other prognostic factors. For the patients who proceed to treatment with surgery, radiation, local ablative therapy or hormonal therapy before progression within the 2 -year follow -up period, the progression time will be censored at 
the time of withdrawal for treatment.  
A recent study in a similar cohort of men undergoing active surveillance (102) reported that PSA kinetics was not closely associated with progression on subsequent surveillance biopsies. In order to address this issue, as a secondary analysis, we will also compare time to progression defined only by [CONTACT_862632] ‚â• 7 for men younger than 70 years and ‚â• 4+3 = [ADDRESS_1202496] enough 
power. For example, if the 2 -year PGR for the control arm is only 10% by [CONTACT_862633], then the log -rank test will have only 50% of power with 418 eligible patients 
with events or full 2 year s of follow -up. 
Time to Treatment:  Probability to proceed to treatment within 2 years (binary 
observation) and time to treatment (censored time to an event observation) will be 
analyzed using the chi -squared test and the log -rank test, respectively. We exp ect that 
the control arm will have more patients receiving treatment and shorter time to treatment 
than the experimental arm because of anxiety.  
QOL:  Quality of life (anxiety and depression, prostate cancer symptom checklist) will be 
compared between the two arms. The time trajectory of QOL will be estimated using the 
generalized estimating equation method based on working independent correlation 
structure (103) and the slope of the time trajectory will be compared between the two arms (104). We will consider taking a log- transformation of QOL observations if it 
improves the linearity of the time trajectory of QOL. The significance of the two arm comparisons will be adjusted for multiple testing among different QOL subscales using 
the methodology of Bang, Ju ng and George (105).  
Dietary Recall: Diets will be evaluated at baseline and at 12 and 24 months by a series 
of three separate 24- hour dietary recalls collected interactively via telephone interview. 
The increase (from baseline) in mean daily intakes of total vegetables, crucifers, tomato 
products, beans/legumes and fat will be compared between arms using a two -sample t-
test at 12 and 24 months. We may consider transforming (e.g. using logarithm) the data to improve normality of the distributions and variance stabilization. Data will be catalogued and analyzed utilizing Minnesota Nutrition Data System (NDS) software 
(Nutrition Coordinating Center, University of Minnesota).  
Plasma carotenoid analyses:  
(1)  Plasma carotenoid concentrations (PCC) will be compared between the two arms 
using a two -sample t- test. A log -transformation of the PCC observations may be 
considered in order to improve the normality of the distributions and variance 
stabilization.  
 (2) PCC will be correlated with PSADT for the patients. Descriptive analysis using scatter 
plots and regression analysis will be conducted. Intervention and known predictors 
including the stratification factors will be adjusted in multivariable analysis.  
(3) Time to pathological progression (i.e., Gleason sum on repeat biopsy ‚â• 7 for men 
younger  than 70 years and ‚â• 4+3 = 7 for men 70 years or older ) will be regressed on 
PCC in AS patients using Cox ‚Äôs regression method . Intervention and  known 
predictors including the stratification factors will be adjusted in multivariable analysis.  
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
40 11.4 Interim A nalysis  
11.4.1  Primary Endpoint  
At each interim analysis, superiority and futility tests on PFS will be conducted as 
follows.  
Superiority:  A superiority test is to test if the experimental arm has a longer PFS 
than the control arm. The first interim analys is for superiority will be conducted when 
[ADDRESS_1202497] (DSMB). The final analysis will be conducted 2 years after the completion of accrual. With the expected study plan, there should be about 4 or  5 interim analyses 
before the final analysis. The superiority testing during the interim analyses will be using one -sided alpha=0.0025. (A one -sided p -value smaller than 0.[ADDRESS_1202498] 
statistic larger than 0 imply the superiority of the experimental arm. ) The final 
analysis will be using one -sided alpha=0.025. Due to the relatively small number of 
interim analyses and the small alpha spending at each interim analysis, the overall type I error rate will not be much larger than the nominal one -sided alpha=0 .025 
(107). 
Futility:  Futility testing will be conducted at the time of each interim analysis 
scheduled for a superiority  test. We will consider stoppi[INVESTIGATOR_862572] 1 -sided p -value is larger than or equal to 0.5 (or the standard ized log-
rank test statistic is smaller than 0) at any interim analysis . 
11.4.[ADDRESS_1202499] depends on the PGR in the two arms. An interim 
analysis will be conducted when 400 patients are enrolled on the study to check i f the 
specified 20% of 2 -year PGR is accurate or not. At the interim analysis, the 2 -year 
PGR of the control arm will be estimated. If the estimate is smaller than 20%, we will 
recalculate the sample size using the estimated 2 -year PGR for the control arm,  
HR=0.472, two sided alpha=0.05 and a power of 80% and consider increasing the sample size by a maximum of 20% of the current sample size. For example, if the estimated 2 -year PGR for the control arm is 18%, then we need 466 eligible patients 
(about 11% in crease from 418 eligible patients). In case the observed progression rate 
is so low that a maximum of 20% increase in sample size does not guarantee a reasonable power for the primary endpoint, we will consider suspending the study for revision.  
11.4.3  Accrual Monitoring  
The accrual rate will be monitored by [CONTACT_862634]‚Äôs Early Stoppi[INVESTIGATOR_862573].  
11.5 Statistical analyses for substudy 151105  
For Objective [IP_ADDRESS], the expression level of Mn SOD, XRCC1 and GST  will be correlated 
with PSADT within each arm. The expression level of these genes may be highly 
correlated with PSADT in the control arm. However, if dietary modification alters th e 
genetic risk , the association may be insignificant or less significant in the experimental  
arm.  
For Objective [IP_ADDRESS], the expression level of Mn SOD, XRCC1 and GST  will be correlated 
with time to pathological progression using Cox regression method within each arm. The expression level of these genes may be highly correlated with time to pathological 
progression in the control arm. However, i f dietary modification alters th e genetic risk , the 
association may be insignificant or less significant in the experimental  arm. 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
41 12.0 REFERENCES  
1. Society AC. Cancer Facts and Figures 2009. 2009 cited; Available from: 
http://cancer.org.  
2. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low -
risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol. 2004; 22(11):2141-2149. 
3. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of inital local 
therapy among men with lower -risk prostate cancer in the united states. JNCI. 2006; 
98(16):1134-1141. 
4. Miller DC, Sanda MG, Dunn RL, et al. Long -term outcomes among localized pr ostate 
cancer survivors: Health -related quality -of-life changes after radical prostatectomy, 
external radiation, and brachytherapy. JCO. 2005; 23(12):2772-2780. 
5. Potosky AL, Davis WW, Hoffman RM, et al. Five -year outcomes after prostatectomy or 
radiother apy for prostate cancer; the prostate cancer outcomes study. JNCI. 2004; 
96(18):1358-1367. 
6. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate -specific antigen 
screening: Lessons from U.S. prostate cancer incidence trends. JNCI. 2002; 94(13):981-
990. 
7. Welch HG, Schwartz LM, Woloshin S. Prostate -specific antigen levels in the united 
states: Implications of various definitions for abnormal. JNCI. 2005; 97(15):[ADDRESS_1202500] a problem with over -detection, 
overtreatment or both? J Urol. 2005; 173(4):1061-1062. 
9. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results. J Urol. 2002; 167(March):1231-1234. 
10. Albertsen PC, Hanley JA, Fine J. 20 -year outcomes following conservative management 
of clinically localized prostate cancer. J Am Med Assoc. 2005; 293(17):2095 -2101. 
11. Klotz L. Active surveillance for prostate cancer: For whom? JCO. 2005; 23(32):8165-8169. 
12. Klotz L, Zhang L, Adam L, Nam R, Mamedov A, Loblaw A. Clinical results of long- term 
follow -up of a large, active surveillance cohort with localized prostate cancer. JCO 2010; 
28(1):126-131. 
13. Khan MA, Carter HB, Epstein JI, et al. Cancer prostate specific antigen dervatives and 
pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003; 170(6):2274-2278. 
14. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate sur gical 
intervention and prostate cancer outcome. J Natl Cancer Inst. 2006; 98(5):355 -357. 
15. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol. 2007; 178(6):2359-2365. 
16. Kahn MA, Partin AW. Expectant management: An option for localized prostate cancer. Prostate Cancer and Prostatic Diseases. 2005; 8:311-315. 
17. Sonn GA, Aronson WJ, Litwin MS. Impact of diet on prostate cancer: A review. Prostate Cance r and Prostatic Dis. 2005; 8(4):304-310. 
18. Chan JM, Giovannucci EL. Vegetables, fruits, associated micronutrients, and risk of prostate cancer. Epi[INVESTIGATOR_19274]. 2001; 23(1):82-86. 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
42 19. Stevens V, Rodriguez C, Pavluck A, McCullough ML, Thun MJ, Calle EE. Folate nutrition 
and prostate cancer incidence in a large cohort of US men. Am J Epi[INVESTIGATOR_5541]. 2006; 163(11):989-996. 
20. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer. Inst. 1995; 87(23):1767-1776. 
21. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. 
J Natl Cancer Inst. 2000; 92(1):61-68. 
22. Kristal AR, Stanford JL. Cruciferous vegetables and prostate cancer risk: Confounding 
by [CONTACT_862635]. Cancer Epi[INVESTIGATOR_9991] & Prevention. 2004; 13(7):1265.  
23. Kristal AR, Lampe JW. Brassica vegetables and prostate cancer risk: A review of the epi[INVESTIGATOR_556324]. Nutrician and Cancer. 2002; 42(1):1-9. 
24. Boileau TWM, Liao Z, Kim S, Lemeshow S, Erdman JW, Clinton SK. Prostate carcinogenesis in N -methyl -N-nitrosourea (NMU) -testosterone- treated rats fed tomato 
powder, lycopene, or energy -restricted diets. JNCI. 2003; 95(21):1578-1586. 
25. Barber NJ, Zhang X, Zhu G, et al. Lycopene inhibits DNA synthesis in primary prostate epi[INVESTIGATOR_862574] a reduced prostate-specific antigen velocity in a phase II clinical study. Prostate Cancer and Prostatic Dis. 2006; 9(4):407-413. 
26. Brooks JD, Paton V. Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent. prostate cancer and prostatic dis. 
1999; 2(S3):S8.  
27. Brooks JD, Paton VG, Vidanes G. Potent induction of p hase II enzymes in human 
prostate cells by [CONTACT_191460]. Cancer Epi[INVESTIGATOR_9991] & Prevention. 2001; 
10(September):949-954. 
28. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. Sulforaphane induces caspase -mediated 
apoptosis in cultured PC -3 human prosta te cancer cells and retards growth of PC -3 
xenografts in vivo. Carcinogenesis. 2004; 25(1):[ADDRESS_1202501]. 2001; 93(24):1872-1879. 
31. Brooks JD, Paton VG, Vidanes G. Potent induction of phase II enzymes in human prostate cells by [CONTACT_191460]. CEBP. 2001;10(9):949-954. 
32. Giovannucci E, Rimm EB, Colditz GA, et al. A  prospective study of dietary fat and risk of 
prostate cancer. J Natl Cancer. Inst. 1993;85(19):1571-1579. 
33. Sinha R, Park Y, Graubard Bl, et al. Meat and meat -related compounds and risk of 
prostate cancer in a large prospective cohort study in the united states. AJE. 2009;170(9):1165-1177. 
34. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epi[INVESTIGATOR_9991] & Prevention. 2007;16(1):63-69. 
35. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epi[INVESTIGATOR_9991] & Prevention. 2006;15(10):1977-1983. 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #[ADDRESS_1202502] a lower risk of 
high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. 
CEBP. 2009; 18(11):2807-2813. 
37. Saxe GA, Major JM, Nguyen JY, Freeman KM, Downs TM, Salem CE. Potential attenuation of disease progression in recurrent prostate cancer with plan -based diet and 
stress reduction. Integ Cancer Ther. 2006;5(3):206-213. 
38. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the 
progression of prostate cancer. J Urol . 2005;174(September):1065-1070. 
39. Ornish D, Magbanua MJM, Weidner G, et al. Changes in prostate gene expression in 
men undergoing an intensive nutrition and lifestyle intervention. PNAS. 2008;105(24):8369-8374. 
40. Parsons JK, Newman VA, Mohler JL, Pi[INVESTIGATOR_18152], Paskett E, Marshall J. The men's eating and living (MEAL) study: A cancer and leukemia group B pi[INVESTIGATOR_862575]. Urology. 2008;72(3):633 -637. 
41. Parsons JK, Newman VA, Mohler JL, Pi[INVESTIGATOR_18152], Fl att S, Marshall J. Dietary modification 
in patients with prostate cancer on active surveillance: A randomized multicentre feasibility study. British Journal of Urology International. 2008; 101(10):1227 -1231. 
42. Parsons JK, Newman VA, Mohler J, et al. Diet ary intervention after definitive therapy are 
localized prostate cancer: Results from a pi[INVESTIGATOR_799]. Can J Urol. 2009; 16(3):4648 -4654. 
43. Wilkinson S, Gomella LG, Smith JA, et al. Attitudes and use of complementary medicine in men with prostate cancer. J  Urol. 2002; 168(6):2505-2509. 
44. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pi[INVESTIGATOR_55243]. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy -prostate 
instrument. Urology. 1997; 50:920 -928. 
45. Roth AJ, Rosenfeld B, Kornblith AB, et al. The memorial anxiety scale for prostate cancer  validation of a new scale to measure anxiety in men with prostate cancer. Cancer. 2003; 97(11):2910-2918. 
46. Roth AJ, Nelson CJ, Rosenfeld B, et al. Assessing anxiety in men with prostate cancer: Further data on the reliability and validity of the memorial anxiety scale for prostate cancer. Psychosomatics. 2006; 47:340-347. 
[ADDRESS_1202503] cancer patients. Psycho -Oncology. 2004; 
13:96-105. 
48. Humphris GM, Rogers S, McNally D, Lee -Jones C, Brown J, Vaughan D. Fear of 
recurrence and possible cases of anxiety and depression in orofacial cancer patients. 
Internatio nal Journal of Oral Maxillofacial Surgery. 2003;32:[ADDRESS_1202504] cancer. Acta Oncology. 1989;28:13 -18. 
50. Wenzel LB, Donnelly JP, Fowler JM, et al. Resilience, reflection and residual stress in 
ovarian cancer survivorship: A gynecologic oncology group study. Psycho -Oncology. 
2002;11:142-153. 
51. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: Development and va lidation of the general measure. JCO. 1993;11:570 -579. 
52. Mehta SS, Lubeck DH, Pasta DJ, Litwin MS. Fear of cancer recurrence in patients undergoing definitive treatment for prostat cancer: Results from Capsure. J Urol. 2003; 170:1931-1933. 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
44 53. Korfage IJ , Essink -Bot ML, Janssens AC, Schroder FH, DeKoning HJ. Anxiety and 
depression after prostate cancer diagnosis and treatment: 5 -year follow -up. Br J Cancer 
Canc. 2006;94(8):1093-1098. 
54. Bandura A. Social foundations of thought and action: A social cognit ive theory. 
Englewood Cliffs, NJ: Prentice -Hall, 1986.  
55. Marks R, Allegrante JP, Lorig K. A review and synthesis of research evidence for self -
efficacy -enhancing interventions for reducing chronic disability: Implications for health 
education practice (p art 1). Health Promotion Practice. 2005;6:37-43. 
56. Bandura A. Self -efficacy: Toward a unifying theory of behavioral change. Psychological 
Review. 1977;84:191-215. 
57. Helgeson VS, Lepore SJ, Eton DT. Moderators of the benefits of psychoeducational 
interv entions for men with prostate cancer. Health Psychology.2006;25:348-354. 
58. Strecher VJ, McEvoy DeVellis B, Becker MH, Rosenstock IM. The role of self -efficacy in 
achieving health behavior change. Health Education & Behavior. 1986;13(1):[ADDRESS_1202505] of a self -management program 
on patients with chronic disease. Effective Clinical Practice. 2001;39:[ADDRESS_1202506] or colorectal cancer treatment improves self -esteem, optimism and self -efficacy. 
Social Science and Medicine. 2006;62:3133-3145. 
61. Boehm S, Coleman -Burns P, Schlenk EA, Funnell MM, Parzuchowski J, Powell IJ. 
Prostate cancer in African -American men: Increasi ng knowledge and self -efficacy. 
Journal of Community Health Nursing. 1995; 12:161 -169. 
62. Merluzzi TV, Martinez Sanchez M. Assessment of self -efficacy and copi[INVESTIGATOR_85509]: 
Development and validation of the cancer behavior inventory. Health Psychology. 1997;16:163-170. 
63. Campbell LC, Keefe FJ, McKee DC, et al. Prostate cancer in African -Americans: 
Relationship of patient and partner self -efficacy to quality of life. Journal of Pain and 
Symptom Management. 2004;18:433-444. 
64. Pi[INVESTIGATOR_18152], Faerber S, Wright FA, et al. Feasibility of a randomized trial of a high -
vegetable diet to prevent breast cancer recurrence. Nutr Cancer. 1997; 28(3):[ADDRESS_1202507] cancer -an overview of the 
intervention. J Amer Diet Assoc. 2005;105(3):382-391. 
66. Pi[INVESTIGATOR_18152], Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatm ent for breast cancer. The women‚Äôs 
health eating and living (WHEL) randomized trial. JAMA. 2007;298(3):[ADDRESS_1202508] cancer survivors. J Nutr. 2004;134:452-458. 
68. Gold EB, Pi[INVESTIGATOR_18152], Natarajan L, et al. Dietary pattern influences breast cancer prognosis in women without hot flashes: The women‚Äôs health eating and living trial.  
Journal of Clinical Oncology. 2009;27(3):352 -259. 
69. Lanza E, Schatzkin A, Daston C, et al. Implementation of a 4- y, high -fiber, high -fruit ‚Äì
and vegetables, low -fat dietary intervention: Results of dietary changes in the polyp 
prevention trial. Am J Clin  Nutr. 2001;74(3):387-401. 
70. Prentice RL, Caan B, Chlebowski RT, et al. Low -fat dietary pattern and risk of invasive 
breast cancer the women‚Äôs health initiative randomized controlled dietary modification trial. J Am Med Assoc. 2006;295(6):629 -642. 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #[ADDRESS_1202509] of a low -fat, high -fiber diet on the 
recurrence of colorectal adenomas: The polyp prevention trial study group. N Engl J 
Med. 2000;342(16):1149-1155. 
72. Bailey DE, Mishel MH, Belyea M, Stewart JL, Mohler J. Uncertainty intervention for 
watchful waiting in prostate cancer. Cancer Nurs. 2004;27(5):339-346. 
73. Barry MJ, Fowler FJ, O‚ÄôLeary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549-1557. 
74. Parsons JK, Wang PY, Bauer DC, Barrett -Connor E, Marshall LM. Prostate cancer and 
lower urinary tract symptoms in community dwelling older men. Presented at the Annual Meeting of the American Urological Association; May 2010; San Francisco, CA. [abstract 494]. J Urol. 2010 (Vol. 183, Issue 4, Supplement, Page e195).  
75. Kristal AR, Arnold KB, Schenk JM, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epi[INVESTIGATOR_5541]. 2008;167(8):[ADDRESS_1202510] symptoms: new approaches to old problems. J Urol. 2007;178:[ADDRESS_1202511] National Health and Nutrition Examination Survey. Urology. 2004;64(3):504 -509. 
78. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Abbreviated vers ion of the Expanded 
Prostate Cancer Index Composite instrument for measuring health- related quality of life 
among prostate cancer survivors. Urology, in press.  
79. Schwarzer R, Renner B. Social -cognitive predictors of health behavior: Action self -
efficacy and copi[INVESTIGATOR_52497] -efficacy. Health Psychol. 2000;19:487-495. 
80. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers the selenium and vitamin E cancer prevention trial (SELECT). Journal of th e American Medical Association. 2009;301(1):E1 -E13. 
81. Etminan M, Takkouche B, Caamano- Isorna F. The role of tomato products and lycopene 
in the prevention of prostate cancer: a meta -analysis of observational studies. Cancer 
Epi[INVESTIGATOR_1948]. 2004 Mar; 13(3):340-5. 
82. Stacewicz -Sapuntzakis M, Bowen PE. Role of lycopene and tomato products in prostate 
health. Biochem Biophys Acta. 2005 May 30;1740(2):202-5. 
83. Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood). 2002 Nov;227(10):881-5. 
84. Eeles, R. A., Kote -Jarai, Z., Giles, G. G. et al.: Multiple newly identified loci associated 
with prostate cancer susceptibility. Nat Genet, 2008.  
85. Gudmundsson, J., Sulem, P., Rafnar, T. et al.: Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet, 2008.  
86. Thomas, G., Jacobs, K. B., Yeager, M. et al.: Multiple loci identified in a genome -wide 
associ ation study of prostate cancer. Nat Genet, 2008.  
87. Amundadottir, L. T., Sulem, P., Gudmundsson, J. et al.: A common variant associated with prostate cancer in European and African populations. Nat Genet, 38: 652, 2006.  
88. Yeager, M., Orr, N., Hayes, R. B. et al.: Genome -wide association study of prostate 
cancer identifies a second risk locus at 8q24. Nat Genet, 39: 645, 2007.  
89. Gudmundsson, J., Sulem, P., Manolescu, A. et al.: Genome -wide association study 
identifies a second prostate cancer susceptibi lity variant at 8q24. Nat Genet, 39: 631, 
2007. 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
46 90. Kibel, A. S., Jin, C. H., Klim, A. et al.: Association between polymorphisms in cell cycle 
genes and advanced prostate carcinoma. Prostate, 68: 1179, 2008.  
91. Lubahn, J., Berndt, S. I., Jin, C. H. et al.: Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate, 70: 646, 2010.  
92. Cheng, I., Plummer, S. J., Jorgenson, E. et al.: 8q24 and prostate cancer: association with advanced disease and meta -analysis. Eur J Hum Genet, 16: 496, 2008.  
93. Beebe- Dimmer, J. L., Levin, A. M., Ray, A. M. et al.: Chromosome 8q24 markers: risk of 
early-onset and familial prostate cancer. Int J Cancer, 122: 2876, 2008.  
94. Duggan, D., Zheng, S. L., Knowlton, M. et al.: Two genome -wide association studies of 
aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst, 99: 1836, 2007.  
95. Mononen, N., Seppala, E. H., Duggal, P. et al.: Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res, 66: 743, 2006.  
96. Chan, J. M., Gann, P. H., Giovannucci, E. L.: Role of diet in prostate cancer development  
and progression. J Clin Oncol, 23: 8152, 2005.  
97. Li, H., Kantoff, P. W., Giovannucci, E. et al.: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Research, 65: 2498, 2005. 
98. Li, H., Stampfer, M. J., Hollis, J. B. et al.: A prospective study of plasma vitamin D 
metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med, 4: 
e103, 2007.  
99. Beer, T. M., Ryan, C. W., Venner, P. M. et al.: Double -blinded randomized study of high -
dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen -
independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol, 25: 669, 2007.  
100. Raaijmakers R, Wildhagen M, Ito K, et al. Prost ate-specific antigen change in the 
European randomized study of screening for prostate cancer, section rotterdam. Urology. 2004;63(2):316-320. 
101. Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: Not as easy as 1, 2, 4. J Urol. 2006;176:1927-1937. 
102. Ross AE, Loeb S, Landis AW, et al. Prostate -specific antigen kinetics during follow-up 
are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010; 28:2810 -2816. 
103. Liang KY, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22. 
104. Jung SH, Ahn C. Sample size estimation for GEE method for comparing slopes in repeated measurements data. Statistics in Medicine. 2003;22:1305-1315. 
105. Bang HJ, Jung SH, George SL. A simulation -based multiple testing procedure and 
sample size calculation. J Biopharmaceutical Stats. 2005;15:957-967. 
106. Fine SW, Epstein JI. (2008). A Contemporary Study Correlating Prostate Needle Biopsy and Radical Prostatectomy Gleason Score. 179(4):1335-1339. 
107. Freidlin B, Korn EL, George SL. Data Monitoring Committees and Interim Monitoring Guidelines. Controlled Clinical Trials. 20:395 -407. 
108. Wu Y, Godoy A, Azzouni F et al . Prostate cancer cells differ in testoster one 
accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5 -alpha reductase inhibit ors. The Prostate 73: 1470- 1482, 2013.  
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #[ADDRESS_1202512] of Dutasteride on the Risk of Prostat e 
Cancer. NEJM 362: 1192-1202, 2010 . 
110. Mohler, James L . Concept and Viability of Androgen Annihilation for Advanced prostate 
Cancer. Cancer (In Press)  
111. Selth  LA, Townley S, Gillis JL et al. Discovery of circulating microRNAs associated with 
human p rostate cancer using a mouse model of disease. International  Journal o f 
Cancer 131: 652- 61, 2011.  
112. Selth LA, Tilley WD, Butler LM. Circulating microRNAs: Macro -utility as markers of 
prostate cancer? Endocr ine-related cancer 19: R99 -R113, 2012. 
113 Sohn I, Kim J, Jung SH, Park C. Gradient lasso for Cox proportional hazards model, 
Bioinformatics, 2009; 25: 1775 -1781. 
 
 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
48 13.0 MODEL  CONSENT  FORM   
The Men‚Äôs Eating and Living (MEAL) Study: A Randomized Trial of 
Diet to Alter Disease Progression in Prostate Cancer Patients on 
Active Surveillance 
 
This is a clinical trial, a type of research study. Your study doctor will explain the clinical trial to 
you. Clinical trials include only patients who choose to take part. Please take your time to make your 
decision. Discuss it with your friends and family. You can also discuss it with your health care team. 
If you have any questions, you can ask your study doctor for more explanation. 
[Attach NCI booklet ‚ÄúTaking Part in Clinical Trials: What Cancer Patients Need to Know‚Äù] You are being asked to take part in this study because you have been diagnosed with prostate cancer 
and are receiving regular follow-up care with your primary physician. 
 
Why is this study being done?  
You are being asked to take part in a research study of men who are undergoing active surveillance 
for their prostate cancer. The purpose of the study is to find out more about how diet may prevent prostate cancer from getting worse. 
 
How many people will take part in this study?  
About 464 men will participate in this study.  
 
What will happen if I take part in this research study?  
Before you begin the study . . .  
You will need to have the following exams, tests or procedures to find out if you can be in the study. 
These exams, tests or procedures are part of regular cancer care and may be done even if you do not 
join the study. If you have had some of them recently, they may not need to be repeated. This will be up to your study doctor. 
‚Ä¢ A complete history and physical exam including a digital rectal exam  
‚Ä¢ A PSA test  
 After you are enrolled in the study, you will be asked to provide about [ADDRESS_1202513] year, your quality of life, function and anxiety. 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
49 Run-in: During a two-week period after enrollment (called ‚ÄúRun-in‚Äù), study researchers from the 
University of [LOCATION_004] at San Diego (UCSD) will call you on three different days over the 
telephone and ask you questions about your medical history and diet. During  these interviews, called 
‚Äú24-hour dietary recalls,‚Äù you will be asked to recall everything you ate and drank during the 
previous 24 hours. You may skip any question that makes you uncomfortable. These telephone interviews will take approximately 20 minute s. 
During the study . . .  
If you are able to complete the three 24-hour dietary recall interviews and you choose to participate in the study, you will be "randomized" into one of the study groups described below. Randomization means that you are put into a  group by [CONTACT_3364]. A computer program will place you in one of the 
study groups. Neither you nor your doctor can choose the group you will be in. You will have an equal chance of being placed in either group. 
Group 1 
If you are in Group 1 (often called "Arm  A") you will be assigned to a program providing you with 
telephone counseling to help change your diet. You will be asked to change your diet to increase the 
amounts of fiber-rich plant foods (vegetables, fruit, whole grains, and beans) that you eat. You will 
receive assistance from diet counselors  at UCSD to help you achieve the dietary goals. These 
counseling calls will take an average of [ADDRESS_1202514] two 
weeks, and gradually decrease in frequency (weekly, bi -monthly, monthly). The counseling calls 
may be monitored and audio-taped for quality assurance purposes. After the first six months, your 
telephone counselor will call you periodically throughout the remainder of the study to check on how you are maintaining the study diet. You will receive a total of 22 calls over the 24-month period. A 
diet intervention manual, a booklet, and regularly scheduled newsletters will also be provided to you. 
Group 2 
If you are in Group 2 (often called "Arm B") you will be assigned to a program providing you with information about diet and cancer. You will receive an initial orientation telephone call that will take about 5 to 10 minutes as well as a booklet containing information about nutrition, exercise and prostate cancer. Regularly scheduled newsletters will also be provided to you. 
Tests and Procedures  
Participants in groups 1 and 2 will complete the tests and procedures listed below. They are part of regular cancer care. 
‚Ä¢ A PSA test every 3 months 
‚Ä¢ A complete h istory and physical exam every 6  months 
‚Ä¢ A digital rectal examination every 12 months at the urologists discretion  
‚Ä¢ A prostate biopsy after you have completed the study (after 24 months) 
 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
50 You will also be asked to do the following while you are on the study: 
‚Ä¢ Every [ADDRESS_1202515] year, your quality of 
life, function and anxiety. 
‚Ä¢ Participate in 24 -hour dietary recall interviews 12 and 24 months after you start the study. 
There will be three interviews at each of these times. Each set of these recalls will happen on 
3 separate days during a scheduled 3-week period. You may skip any question that makes you uncomfortable. 
‚Ä¢ Provide about [ADDRESS_1202516]  X X X X X X X X 
Clinic Visit*   X  X  X  X 
Diet Recall     X    X 
Questionnaires   X  X  X  X 
Blood for carotenoid and 
cholesterol levels    X    X 
Prostate Biopsy         X 
Telephone Counseling  For patients in Group 1 only: 22 telephone calls over 2 years 
‚Ä¢ Includes history and physical, height, weight, and a digital rectal examination every [ADDRESS_1202517] completed the study, you will continue with your usual cancer care. 
 
How long will I be in the study?  
You will be in the study for 2 years. 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
51 Can I stop being in the study?  
Yes. You can decide to stop at any time. Tell the study doctor or nurse if you are thinking about 
stoppi[INVESTIGATOR_59917].  
It is important to tell your study doctor if you are thinking about stoppi[INVESTIGATOR_862576]. 
The study doctor may stop you from taking part in this study at any time if he/she believes it is in 
your best interest; if you do not follow the study rules; or if the study is stopped. 
 
What side effects or risks can I expect from being in the study?  
You may have side effects while on the study. Everyone taking part in the study will be watched carefully for any side effects. However, doctors don't know all the side effects that may happen. You 
should talk to your study doctor about any side effects that you have while taking part in the study. 
Possible risks from changing your diet  
‚Ä¢ Your skin, especially on the palms of your hands and the soles of your feet, may become yellow because of a diet high in carotenoids. 
‚Ä¢ You may become bloated or have a lot of gas for a short period because you may be eating more vegetables and dietary fiber than usual. You may get diarrhea or become constipated at first, but only until your body can adjust to your new diet. 
Other risks  
‚Ä¢ There may be a small risk in the process of drawing blood. You may faint or become dizzy. 
You may feel a little pain or discomfort as the needle goes through the skin. Some bleeding or bruising may occur at the site where blood is drawn. Pressing hard on the spot for 1 or 2 
minutes after the needle is removed will help to prevent this. Very rarely, your arm may swell 
or become infected.  
 
Are there benefits to taking part in the study?  
There will be no direct benefits to you other than those associated with changing your diet. The investigators may learn more about how diet plays a role in changing the way prostate cancer can 
spread in the body. This information could help future prostate cancer patients. 
It is important to remember that while there may be benefits , you should continue to be followed by 
[CONTACT_862636].  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #[ADDRESS_1202518] if I do not take part in this study?  
You may choose not to take part in this study. If you do not take part in the study, you should discuss 
with your doctor the appropriate treatment or surveillance plan for your prostate cancer. Those who 
choose not to participate in this study will continue under the care of their doctors for prostate cancer. 
You may also choose to take part in another research study.  
Talk to your doctor about your choices before you decide if you will take part in this study. 
 
Will my medical information be kept private?  
We will do our best to make sure that the personal information in your medical record will be kept 
private. However, we cannot guarantee total privacy. Your personal information may be given out if 
required by [CONTACT_2371]. If information from this study is published or presented at scientific meetings, your 
name [CONTACT_3381]. 
In order for the diet counselors at the University of [LOCATION_004] at San Diego to contact [CONTACT_10825], it will be 
necessary for you to fill out a contact [CONTACT_862637], address, 
telephone number, and other personal information. Your contact [CONTACT_862638]. 
Organizations that may look at and/or copy your medical record for research, quality assurance, and 
data analysis include:  
‚Ä¢ Alliance for Clinical Trials in Oncology (Alliance) ‚Ä¢ National Cancer Institute  
‚Ä¢ The Cancer Trials Support Unit (CTSU), a service sponsored by [CONTACT_29630] 
(NCI) to provide greater access to cancer trials, may also view your records if you are participating in this trial through one of their institutions. 
 
The Alliance has received a Certificate of Confidentiality from the federal government, which will 
help us to protect your privacy. The Certificate protects against the involuntary release of information 
about you collected during the course of the study. The researchers involved in this project may not 
be forced to identify you in any legal proceedings (criminal, civil, administrative, or legislative) at 
the federal, state or local level. However, some information may be required by [CONTACT_574913], Drug, and Cosmetic Act, the U.S. Department of Health and Human Services, or for purposes of program review or audit. Also, you may choose to voluntarily disclose the protected information under certain circumstances. For example, if you or your guardian requests  the release of information 
about you in writing (through, for example, a written request to release medical records to an insurance company), the Certificate does not protect against that voluntary disclosure. 
 
What are the costs of taking part in this st udy? 
You and/or your health plan/insurance company will be responsible for the charges related to your 
cancer care. All study measurements and materials directly related to the research will be provided to 
you free of charge. 
You will be responsible for the cost of the food specified by [CONTACT_1758]. You will not be paid for taking part in this study. 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
53 For more information on clinical trials and insurance coverage, you can visit the National Cancer 
Institute‚Äôs Web site at http://cancer.gov/clinical trials/under standing/insurance-coverage. You can 
print a copy of the ‚ÄúClinical Trials and Insurance Coverage‚Äù information from this Web site. 
Another way to get the information is to call 1-800-4-CANCER (1-800-422- 6237) and ask them to 
send you a free copy. 
 
What happens if I am injured because I took part in this study?  
It is important that you tell your study doctor  _______________   if you feel that you have been 
injured because you took part in this study. You can tell the doctor in person or call him at 
___________________. 
You will get medical treatment if you are injured as a result of taking part in this study. You and/or 
your health plan will be charged for this treatment. The study will not pay for medical treatment. 
 
What are my rights if I take part in this  study? 
Taking part in this study is your choice. You may choose either to take part or not to take part in the study. If you decide to take part in this study, you may leave the study at any time. No matter what 
decision you make, there will be no penalty  to you and you will not lose any of your regular benefits. 
Leaving the study will not affect your medical care. You can still get your medical care from your 
institution.  
We will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study.  
A Data and Safety Monitoring Board will be regularly meeting to monitor safety and other data related to this study. The Board members may receive confidential patient information, but they will not receive your name [CONTACT_862646] [CONTACT_2300]. 
It may be necessary to contact [CONTACT_147286] a future date regarding new information about the intervention 
you have received. For this reason, we ask that you notify the institution where you participated in 
the study of any changes in address. If you move, please provide your new address to:  
In the case of injury resulting from this study, you do not lose any of your legal rights to seek 
payment by [CONTACT_3368]. 
 
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
54 Who can answer my questions about the study?  
You can talk to your study doctor about any questions or concerns you have about this study. Contact 
[CONTACT_6814] ____________________   at   ____________________. 
 
For questions about your rights while taking part in this study, call the ________________ 
Institutional Review Board (a group of people who review the research to protect your rights) at 
___________________. 
 
  
RELATED STUDIES 
Please note: The following section of the informed consent form is about additional research 
studies that are being done with people who are taking part in the main study. You may take 
part in these additional studies if you want to. You can still be a part of the main study even if you say ‚Äúno‚Äù to taking part in any of these additional studies.  
The results of these research studies will not be provided to you or your doctor, nor will the results have any effect on your treatment. It is unlikely that what we learn from these studies will have a 
direct benefit to you. However, the information learned from these studies may benefit other patients 
in the future. 
The results from these studies may be published, but individual patients will not be identified in these 
publications. 
There will be no charge to you for participating in these research studies. Your sample and 
information will only be used for research and will not be sold. The research done with your sample 
may help to develop new products in the future. 
The greatest risk to you is the release of information from your health records. We will do our best to 
make sure that your personal information will be kept private. The chance that this information will be given to someone inappropriate is very small. 
In the future, people who do research may need to know more about your health. While the Alliance 
for Clinical Trials in Oncology  may give them reports about your health, it will not give them your 
name, address, phone number, or any other information that will let the researchers know who you 
are.  
If you decide now to participate and then change your mind at any time about participating in these 
studies for any reason, you should contact [CONTACT_862639]. The sample will then no longer be used for resea rch. It will either 
be destroyed or returned to your institution for storage. The sample will also be returned to your institution upon request if needed for any other medical or legal reasons. 
You can say ‚Äúyes‚Äù or ‚Äúno‚Äù to the following study. No matter what you decide to do, it will not affect 
your care. 
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
55 Studies on blood and tissue  (includes genetic studies):  
Blood: Study researchers would like to collect additional samples of your blood. The researchers 
would like to conduct other studies on carotenoid and cholesterol levels in your blood. Also, they 
would like to investigate whether substances in your blood (sometimes called tumor markers) are related to the way that your body responds or doesn't respond to changes in your diet.  
In addition to the studies on carotenoid and cholesterol levels, researchers wish to determine whether there is a relationship between genes and the severity of your disease. In order to study genes, the 
DNA must be removed from your blood sample. DNA is the substance that makes up your genes. 
Genes are the units of inheritance that are passed down from generation to generation. They are responsible for eye color, hair color, blood type, and hundreds of other traits. 
If you agree to these additional studies, about 4 teaspoons of additional blood would be collected at the beginning of the study and then about 2 teaspoons of blood would be colle cted 12 and 24 months 
after you start the study. 
Tissue: A section of the material from the prostate biopsy that was used to diagnose your prostate 
cancer was reviewed by [CONTACT_862640]. Study researchers would also li ke to test additional sections of this tissue from this prostate biopsy to look at tissue 
tumor markers. Investigators want to look at how the tumor is growing, if some hormones were 
present, and to examine genetic activity in your biopsy tissue. No extra prostate biopsies would be 
needed for these extra tissue studies. Tissue would be used from your prostate biopsies already done as part of the main study. 
About genetic studies:  
New scientific tools will now allow researchers to look at your whole DNA, not just one part or one gene. This kind of research can provide information to researchers about the development of cancer 
and response to treatment. It can also provide information about a variety of other conditions and 
diseases, including heart disease, diabetes and Alzheimer‚Äôs disease.  
Because the information gained in these genetic studies can be very useful to the research community, the National Institutes of Health (NIH) has requested that these data be placed in a central database housed at the NIH. The goal is to speed up the process for discovery of new 
treatments, prevention and diagnosis of disease. Researchers must get approval from the NIH before 
they can access the r esearch results and health -related information from your specimen. All 
information will be coded with a unique number. Researchers will not have access to your identity; they will only see coded information. 
The greatest risk to you is the release of information from your health records. We will do our best to 
make sure that your personal information will be kept private. The chance that this information will 
be given to someone is very small. Below are some of the steps we have taken to protect your privacy and confidentiality: 
  
CALGB [ZIP_CODE]  
Version Date 09/26/18 Update #10  
56 ‚Ä¢ Blood and tissue samples will be stored at a n Alliance laboratory. The Alliance Statistics and 
Data Center will perform all analyses of data and store all study results. Your blood and 
tissue samples will not be stored with your name [CONTACT_96179]. Instead, they will be labeled with a 
special Alliance  identification number. The only location where your name [CONTACT_862647] . The 
greatest effort will b e made to see that all personal information that can identify you is kept 
under conditions that protect your privacy. 
‚Ä¢ Information about your participation in this study and results of any tests performed on your 
samples will be kept only at the Alliance Statistics and Data  Center. This information will not 
be made available to your doctors or to individual researchers at the Alliance . Test results 
from this study will not be put in your medical records. All study information, including test results, is st ored under conditions that limit access in order to protect the privacy of the 
people participating in the study. 
‚Ä¢ The Alliance has received a Certificate of Confidentiality from the federal government, 
which will help us to protect your privacy. More information about the Certificate can be 
found in the paragraph ‚ÄúWill my medical information be kept private?‚Äù 
‚Ä¢ A federal law (Genetic Information Non-Discrimination Act, GINA) will help lower the risk from health insurance or employment discrimination on the basis of genetic information. The 
federal law does not include other types of misuse by [CONTACT_862641], long -term care or 
disability insurance. If you want to learn more about the GINA Law, which went into effect 
in 2009, you can find information about it on the internet or ask the study staff. In addition to 
the federal law, some states have laws that also help protect against genetic discrimination.  
While we believe that the risks to you and your family are very low, we cannot tell you exactly what 
all of the risks are from taking part in genetic research studies. Your privacy and confidentiality will 
be protected to the fullest extent possible. 
You have the right to participate in this study without participating in the proposed research studies 
on your blood samples. Please read the sentence below and think about your choice. After reading 
the sentence, please mark your choice and provide the current date. No matter what you decide to 
do, it will not affect your care.  
 
 
1) I agree that my specimens may  be used for the research described above.  
_____  Yes _____  No Initials  _____ 
  
  
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
57 Storage of your specimens:  
The researchers would also like to store any blood that is not used up by [CONTACT_862642]. These samples may be stored indefinitely. You can still take part in the treatment study, and the research study described above without giving your consent for your samples to be stored. 
 
It is not possible for you or the Alliance to know what studies of cancer may be appropriate in the 
future. We ask that you give permission in advance for other studies to be performed using the blood without being re-contact[CONTACT_862643].   
2) My specimens may be kept for future unknown use in research to learn about, 
prevent, treat, or cure cancer.  
_____  Yes _____  No Participant  _____________________ Date _____ 
3) My specimens may be kept for research about other health problems (for example: 
causes of diabetes, Alzheimer‚Äôs disease and heart disease.  
_____  Yes _____  No Participant  _____________________ Date _____ 
4) My doctor or someone from CALGB/Alliance  may contact [CONTACT_862644].  
_____  Yes _____  No Participant  _____________________ Date _____ 
Where can I get more info rmation?  
You may call the National Cancer Institute‚Äôs Cancer Information Service at:  1-800-4-CANCER ([PHONE_1131]) 
 
You may also visit the NCI web site at http://cancer.gov/  
‚Ä¢ For NCI‚Äôs clinical trials information, go to: http://cancer.gov/clinical trials/  
‚Ä¢ For NCI‚Äôs general information about cancer, go to http://cancer.gov/cancerinfo/  You will get a copy of this form. If you want more information about this study, ask your study doctor. 
Signature  
I have been given a copy of _____ [insert total of number of pages] pages of this form. I have read it or it has been read to me. I understand the information and have had my questions answered. I agree to take part in the study. 
 
Participant________________________________         Date___________________  Participant Name (please print) _____________________________________   
CALGB [ZIP_CODE] 
Version Date 09/26/18 Update #10  
58 14.0 MODEL  CONSENT  FORM:  ADDENDUM FOR P ATIENTS WHO CON SENTED TO PARTICIPATE IN THE 
EMBEDDED COMPANION S TUDY TO [ZIP_CODE]  PRIOR TO THE APPROV AL OF UPDATE 8 
The Men‚Äôs Eating and Living (MEAL) Study: A Randomized Trial of 
Diet to Alter Disease Progression in Prostate Cancer Patients on 
Active Surveillance 
You are either currently participating in, or have previously participated in the research study called 
CALGB [ZIP_CODE]. You are being contact[CONTACT_862645].   
Additional related s tudies  
At the time that you enrolled to CALGB [ZIP_CODE], a section of the material from the prostate biopsy that was used to diagnose your prostate cancer was reviewed by [CONTACT_862640]. Study researchers would now like t o test additional sections of this tissue from that 
prostate biopsy to look at tissue tumor markers. Investigators want to look at how the tumor is 
growing, if some hormones were present, and to examine genetic activity in your biopsy tissue. No 
extra prostate biopsies would be needed for these extra tissue studies. If you agree to these additional related studies, tissue from your previous prostate biopsy would be sent to the Alliance Biobank for this research.  
The risks and protections regarding the additional studies on the blood samples that were described to 
you in the consent form you previously signed will apply to this additional study on your tissue sample. You have the right to refuse that your tissue be used for this additional study, and your decision will not affect whether you may continue with the main CALGB [ADDRESS_1202519] been given a copy of all _____ [insert total of number of pages]  pages of this form. I have 
read it or it has been read to me. I understand the information and have had my questions answered. I 
agree to take part in this study. 
 
Participant  ________________________________ 
 
Date _____________________________________ 
  